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SUMMARY 
Despite significant progress in cancer research, effective cancer treatment is still a            
challenge. Cancer treatment approaches are shifting from standard cytotoxic         
chemotherapy regimens towards a precision oncology paradigm, where a choice of           
treatment is personalized, i.e. based on a tumor’s molecular features. In order to             
match tumor molecular features with therapeutics we need to identify biomarkers of            
response and build predictive models. Recent growth of large-scale         
pharmacogenomics resources which combine drug sensitivity and multi-omics        
information on a large number of samples provides necessary data for biomarker            
identification and drug response modelling. However, although many efforts of using           
this information for drug response prediction have been made, our ability to            
accurately predict drug response using genetic data remains limited. 
 
In this work we used pharmacogenomics data from the largest publicly available            
studies in order to systematically assess various aspects of the drug response            
model-building process with the ultimate goal of improving prediction accuracy.  We           
applied several machine learning methods (regularized regression, support vector         
machines, random forest) for predicting response to a number of drugs. We found             
that while accuracy of response prediction varies across drugs (in most of the             
cases R 2 values vary between 0.1 and 0.3), different machine learning algorithms            
applied for the the same drug have similar prediction performance. Experiments           
with a range of different training sets for the same drug showed that predictive              
power of a model depends on the type of molecular data, the selected drug              
response metric, and the size of the training set. It depends less on number of               
features selected for modelling and on class imbalance in training set. We also             
implemented and tested two methods for improving consistency for         
pharmacogenomics data coming from different datasets. 
 
We tested our ability to correctly predict response in xenografts and patients using             
models trained on cell lines. Only in a fraction of the tested cases we managed to                
get reasonably accurate predictions, particularly in case of response to erlotinib in            
the NSCLC xenograft cohort, and in cases of responses to erlotinib and docetaxel             
in the NSCLC and BRCA patient cohorts respectively. 
 
This work also includes two applied pharmacogenomics analyses. The first is an            
analysis of a drug-sensitivity screen performed on a panel of Burkitt cell lines. This              
combines unsupervised data exploration with supervised modelling. The second is          
an analysis of drug-sensitivity data for the DKFZ-608 compound and the generation            
of the corresponding response prediction model. 
 
In summary, we applied machine learning techniques to available high-throughput          
pharmacogenomics data to study the determinants of accurate drug response          
prediction. Our results can help to draft guidelines for building accurate models for             
personalized drug response prediction and therefore contribute to advancing of          
precision oncology. 
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ZUSAMMENFASSUNG 
Trotz erheblicher Fortschritte in der Krebsforschung bleibt die effektive Behandlung          
von Krebs eine Herausforderung. Die Behandlungsansätze verschieben sich von         
der üblichen zytotoxischen Chemotherapie hin zu einem präzisionsonkologischen        
Modell, in dem die Behandlungswahl personalisiert ist und auf den molekularen           
Eigenschaften des Tumors basiert. Um passende Therapeutika für die molekularen          
Krebseigenschaften zu finden, müssen Biomarker für das Therapieansprechen        
identifiziert und prädiktive Modelle erstellt werden. Das jüngste Wachstum an          
umfassenden pharmacogenomischen Ressourcen, die Wirkstoffsensitivität und      
multi-omics Informationen einer großen Anzahl an Proben vereinen, liefern die          
nötigen Daten für Biomarker-Identifizierung und Erstellung von Modellen zum         
Wirkstoffansprechen. Trotz vieler Bemühungen diese Informationen zur Vorhersage        
von Therapieansprechen zu nutzen, bleiben die Möglichkeiten, Wirkstoffansprechen        
präzise aus genetischen Daten vorherzusagen, begrenzt. 
 
In der vorliegenden Arbeit wurden pharmacogenomische Daten der größten         
öffentlich verfügbaren Studien genutzt, um systematisch verschiedene Aspekte der         
Erstellungsprozesse von Wirkstoff-Ansprech-Modellen einzuschätzen, mit dem      
ultimativen Ziel die Vorhersagegenauigkeit zu verbessern. Mehrere maschinelle        
Lernverfahren (regularisierte Regression, Support Vector Machinen, Random       
Forest) wurden auf eine Vielzahl von Wirkstoffen angewandt, um das Ansprechen           
vorherzusagen. Dabei wurde herausgefunden, dass die Genauigkeit der        
Ansprechvorhersage von Wirkstoff zu Wirkstoff variiert (in dem meisten Fällen          
liegen die R 2 -Werte zwischen 0.1 und 0.3). Die verschiedenen Algorithmen für           
maschinelles Lernen weisen aber ähnliche Prognosefähigkeiten auf, wenn sie auf          
den gleichen Wirkstoff angewandt werden. Experimente mit einer Reihe         
verschiedener Trainingsdatensätze für den gleichen Wirkstoff haben gezeigt, dass         
die Vorhersagekraft eines Modells von der Art der molekularen Daten, der           
gewählten Metrik für Wirkstoffansprechen und der Größe des Trainingsdatensatzes         
abhängt. Es hängt dagegen weniger von der Anzahl der Merkmale, die für die             
Modellierung gewählt wurden, oder dem Ungleichgewicht der Klassen im         
Trainingsdatensatz ab.  Außerdem wurden zwei Methoden implementiert und        
getestet, die die Konsistenz von Pharmacogenomicsdaten aus verschiedenen        
Datensätzen verbessert. 
 
Desweiteren wurde evaluiert, ob das Ansprechen in Xenotransplantaten und         
Patienten mit Hilfe von Modellen, die auf Zelllinien trainiert wurden, vorhergesagt           
werden kann. Hinreichend genaue Prognosen konnten nur in einem Bruchteil der           
getesteten Fälle erreicht werden, vor allem in Bezug auf Erlotinib in der NSCLC             
Xenotransplantat Kohorte beziehungsweise Erlotinib und Docetaxel in den NSCLC         
und BRCA Patientenkohorten. 
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Diese Arbeit beinhaltet auch zwei angewandte pharmakogenomische Analysen. Die         
erste ist eine Analyse eines Wirkstoffempfindlichkeitscreenings, welches auf einer         
Reihe von Burkitt Zelllinien basiert. Dabei wurde unüberwachte Datenerkundung mit          
überwachter Modell-Erstellung kombiniert. Die zweite ist eine Analyse der         
Wirkstoffempfindlichkeitsdaten für den DKFZ-608 Wirkstoff und die Erstellung des         
zugehörigen Modells zur Ansprechensvorhersage. 
 
Zusammengefasst wurden maschinelle Lernverfahren auf verfügbare      
Hochdurchsatz-Pharmacogenomicsdaten angewandt, um die Einflussfaktoren auf      
präzise Vorhersagen über Wirkstoffansprechen zu untersuchen. Die Ergebnisse        
können das Konzipieren von Richtlinien zur Erstellung genauer Modelle für das           
personalisierte Vorhersagen von Wirkstoffansprechen unterstützen und somit einen        
Beitrag für den Fortschritt der Präzisionsonkologie leisten. 
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LIST OF ABBREVIATIONS 
 
AUC Area under the curve (drug response metric) 
AUROC Area under the receiver operating characteristic (ROC) curve (classification         
accuracy metric) 
BGP Binary gene pairs 
CCLE Cancer Cell Line Encyclopedia  
CI Combination index  
CTRP Cancer Therapeutics Response Portal  
DREAM Dialogue for Reverse Engineering Assessments and Methods (consortium) 
FDA Food and Drug Administration (US federal agency) 
FS Feature selection 
gCSI Genentech Cell Line Screening Initiative 
GDSC Genomics of Drug Sensitivity in Cancer 
GLDS General level of drug sensitivity 
IC 50 Half-maximal inhibitory concentration 
ML Machine learning 
NIBR PDXE Novartis Institutes of Biomedical Research patient-derived tumor xenograft        
encyclopedia 
PC Principal component 
PCA Principal component analysis 
PDX Patient-derived xenograft 
R 2 R-squared, coefficient of determination 
RF Random Forest 
RMSE Root of mean squared error 
SVM Support vector machines 
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1 INTRODUCTION 
Personalized oncology is an approach to cancer treatment that seeks to identify            
effective therapeutic strategies for every patient. This identification is possible via           
integration of genomic and drug-sensitivity data and subsequent generation of          
drug-response associations. While personalized approach is not yet a part of           
routine care for most cancer patients, its abundance is continuing to grow due to the               
progress in areas of multi-omics tumor characterization, drug-sensitivity testing and          
data integration. In this thesis we examine applicability of pharmacogenomics data           
(genomics + drug response) available up to date for accurate drug response            
prediction using machine learning models. 
 
In this introductory chapter I’ll start with giving an overview of general principles of              
cancer treatment, then we’ll discuss drug therapy with an emphasis on targeted            
therapies. After that I’ll describe experimental drug sensitivity testing and large           
pharmacogenomics projects that generated data we used in our analyses, also we’ll            
discuss a problem with (in)consistency between pharmacogenomics data coming         
from different projects. In the end of the chapter I’ll introduce basic machine learning              
concepts and describe machine learning methods we used in our analyses for            
building predictive drug response models. 
1.1 General principles of cancer treatment 
The standard treatment modalities for patients with cancer include surgery,          
radiotherapy and drug therapy. 1 Surgery aims to physically cut out the tumor.            
Radiotherapy uses ionizing radiation (e.g. X-rays) to kill cancer cells and shrink            
tumors. Drug therapy is the treatment of cancer with single drugs or drug             
combinations.  
 
The choice of treatment approaches depends on 3 groups of factors: tumor factors,             
treatment factors and patient factors. Tumor factors include type of cancer           
(characterized by histological and molecular information) spread of cancer and its           
stage. Treatment factors include availability of treatment, evidence on its efficacy for            
given disease and side effects.  
Patient factors include patient performance status and patient preferences. 1  
 
With respect to goal of cancer treatment, the are two types of therapy: curative and               
palliative. The goal of curative therapy is to cure the patient of cancer. In cases               
where cure is not feasible (e.g. when cancer is metastatic) the therapy is palliative,              
i.e. the goal is to improve symptoms, quality of life and prolong survival through              
tumor stabilisation or shrinkage. 2 
 
There is a special terminology for describing the outcome of treatment. Complete            
disappearance of all tumor would constitute a complete clinical remission. If tumor            
have been reduced by 50% or more it would be described as partial clinical              
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remission. In case when tumor is unchanged by treatment it can be described as              
stable disease. If the tumors grew during the treatment, this would be considered as              
progressive disease. There is a difference between “complete remission” and          
“cure”, since the latter term means not only that there is no traces of cancer after                
treatment but also that cancer will never come back therefore term “cure” can be              
truly applied only in retrospect. Indeed, some patients who achieve even a complete             
remission may have a regrowth of cancer after a disease-free period. Such            
regrowth is referred to as a recurrence or relapse of the tumor. 1 
1.2 Drug therapy. Targeted/non-targeted therapy     
dichotomy 
Drug therapy (or systemic therapy) is a mainstay of treatment for most types of              
cancer. 2 Drug therapies work in various ways to destroy cancer cells, stop them             
from spreading or slow down their growth. Usually cancer drug treatments fall into             
four categories: conventional cytotoxic chemotherapy, hormonal therapy, targeted        
therapy and immunotherapy. 3 Hormonal therapy exploits dependence of some         
cancers on hormones and stops tumor growth by blocking certain hormones e.g.            
estrogen in breast cancer or testosterone in prostate cancer. Immunotherapy is a            
diverse set of therapeutic strategies designed to induce patient’s own immune           
system to fight the tumor; these approaches exploit the fact that cancer cells often              
have molecules on their surface that can be detected by the immune system,             
known as tumor antigens, they are often proteins or other macromolecules. 4 
 
Our work focuses on drug response prediction for cytotoxic chemotherapeutics and           
targeted therapies. These two categories form a dichotomy with respect to drug’s            
selectivity. Most cytotoxic chemotherapy drugs are agents designed to attack          
actively dividing cells, based on the fact that cancer cells divide more rapidly than              
normal cells. However, cytotoxic chemotherapeutics are unspecific and also         
destroy some normal cells causing unwanted toxic effects. On the other hand a             
targeted therapy has a specific molecular target which is restricted to and critical for              
cancer cell growth, therefore targeted therapy shouldn’t be toxic for patient’s normal            
tissue. 2  Let’s review both chemotherapy and targeted therapy in greater detail. 
1.2.1 Cytotoxic chemotherapy 
Chemotherapy acts by interfering with basic properties of cancer cell, such as            
growth and proliferation, DNA synthesis, metabolism and other essential cellular          
functions. Regardless of the specific mechanism it generally kills a cancer by            
activating the apoptosis. 1  
The era of chemotherapy began in the 1940s when nitrogen mustards and antifolate             
drugs were first used for cancer treatment. 5 Since then many chemicals have been             
studied and tested for their effects on cancer cells, and a large number of              
compounds now play a role in cancer treatment. They can be broadly separated             
into categories based on mechanism of action (Table 1). 
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Table 1. Chemotherapy agents and their mechanisms of action. Adapted from Pardee &             
Stein. 1  
Category Mechanism of action Drugs 
Alkylating agents; 
Platinum-based agents 
Cause breaks or mutations 
in DNA 
cyclophosphamide, 
temozolomide; 
cisplatin, oxaliplatin, 
carboplatin 
Anti-metabolites Block DNA synthesis methotrexate, cytarabine, 
5-fluorouracil, capecitabine, 
gemcitabine, 6-mercaptopurine 
Anti-tumor antibiotics Bind to DNA and prevent 
RNA synthesis leading to 
cell death 
doxorubicin, epirubicin, 
bleomycin, mitoxantrone 
Topoisomerase inhibitors Block unwinding of DNA 
and therefore interfere with 
replication and transcription 
etoposide, irinotecan, 
topotecan 
Microtubule inhibitors Prevent microtubules in 
cells from supporting cell 
division 
paclitaxel, docetaxel, 
vincristine, vinblastine 
 
As the majority of chemotherapeutic are cytotoxic i.e. their function is to kill rapidly              
dividing cells, they are invariably associated with a range of toxic side effects due to               
lack of specificity to cancer cells. These side effects are especially prevalent in             
cells/tissues with a high turnover including skin, gastrointestinal tract and bone           
marrow and lead to some adverse reactions. Hair loss, mucositis (inflammation of            
the lining of the digestive tract), diarrhoea, vomiting, myelosuppression (decreased          
production of blood cells) are all common side effects that can have devastating             
morbidity and can be fatal. 2 
1.2.2 Targeted therapy 
Recently the ability to characterize specific gene mutations in different cancers, and            
a greater biological understanding of the cellular events and pathways driving           
carcinogenesis, has led to new approaches to cancer treatment. Such approaches,           
called targeted therapy, are aimed at specific molecular alterations that contribute to            
the growth of cancer cells and therefore they deliver growth inhibitory or cytotoxic             
effects in a much more cell-specific manner. 3 Targeted therapies can be divided into             
two categories -- small-molecule inhibitors and monoclonal antibodies (see Table 2).           
Small molecule inhibitors can pass through cell membrane and inhibit          
mutated/overexpressed proteins critical for cancer growth. Monoclonal antibodies        
act on the surface of cancer cell by binding to specific cell surface proteins which               
prevents growth signal transmission or induces the immune response. 1 
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Table 2. Examples of targeted therapies. Adapted from Pardee & Stein. 1  
Drug Major targets Disease 
Small molecule 
Sorafenib BRAF, VEGFR; EGFR Renal cell cancer; liver cancer 
Sunitinib VEGFR, c-kit, FLT3 Renal cell cancer; GI stromal tumor 
Erlotinib EGFR Non-small cell lung cancer; pancreatic 
cancer 
Gefitinib EGFR Non-small cell lung cancer 
Bortezomib Proteasome Myeloma 
Lapatinib Her-2/Neu, EGFR Breast cancer 
Imatinib Bcr-Abl; c-kit Chronic myelocitic leukemia; acute 
lymphoblastic leukemia; GI stromal 
tumor, mastocytosis 
Dasatinib Bcr-Abl; c-kit Chronic myelocitic leukemia; acute 
lymphoblastic leukemia 
Monoclonal antibodies 
Bevacizumab VEGF Colorectal cancer; non-small cell lung 
cancer 
Rituximab CD20 B-cell lymphoma 
Cetuximab EGFR Colorectal cancer; head and neck 
cancer 
Gemtuzumab CD33 Acute myelogenous leukemia 
Alemtuzumab CD52 Chronic lymphocytic leukemia 
Y-ibritumomab CD20 Non-Hodgkin’s lymphoma 
 
During the last decade efforts of international consortia (with TCGA 6 and ICGC 7            
being most prominent ones) produced detailed characterization of the common          
somatic genetic alterations in a variety of different tumor types. Theoretically those            
driver alterations (i.e. alterations that cause cancer phenotype) which are druggable           
(i.e. can blocked/inhibited by therapeutics in a specific manner) present potential           
treatment opportunities. Druggable alterations have been identified in a substantial          
proportion of several major tumor types  (Fig. 1). Many of these mutations encode             
targets of already approved drugs. 8 
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Figure 1. Genomic alterations affecting actionable signaling pathways in common solid           
tumors. “Pie charts for (A) lung adenocarcinoma, (B) lung squamous cancer, (C) breast             
cancer, (D) colorectal cancer, (E) melanoma, and (F) head and neck squamous cancer show              
the distribution of known recurrent driver cancer gene mutations, with emphasis on those             
genes/pathways targeted by ≥ one anticancer agent that is either FDA approved or in clinical               
development; other denotes proportion of tumors containing undruggable drivers or where           
driver gene has not yet been conclusively delineated. Bar graphs are shown for (G) ovarian               
cancer and (H) glioblastoma multiforme, where plausibly actionable cancer gene mutations           
are frequent but not mutually exclusive; in these cases, driver genes are commonly             
dysregulated by chromosomal copy number alterations as well as base mutations” (Figure            
taken from Garraway 8 ). 
 
Indeed, due to unprecedented advances in cancer drug development since the           
beginning of 21st century a broad spectrum of therapeutics directed against multiple            
effector proteins spanning most cancer signaling pathways has entered clinical          
trials and, in some cases, clinical practice 8 (Fig 2). The recent analyses showed             
that by 2017 there were around 90 FDA approved targeted therapies with more than              
100 associated molecular targets 9,10 (The updated list of FDA approved drugs is            
available at mycancergenome.org web resource 11 ). 
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Figure 2. Spectrum of targeted anticancer agents in clinical development. “Exemplary           
oncoproteins and cancer pathways targeted by at least one US Food and Drug             
Administration–approved or developmental drug are indicated. Examples include receptor         
tyrosine kinases (orange); mitogen-activated protein kinase pathway proteins (RAS, RAF,          
MEK, and ERK; light blue); phosphoinositol-3 kinase (PI3K) pathway components (PI3K,           
phosphoinositide-dependent protein kinase 1 [PDK1], AKT, mammalian target of rapamycin          
[mTOR], and ribosomal S6 kinase [S6K]; pink); the RAC/PAK pathway (dark blue), the Janus              
kinase (JAK) –signal transducer and activator of transcription pathway (STAT) pathway; Notch            
(gray); the sonic hedgehog pathway, including patched (PTCH) and smoothened (SMO)           
proteins (green); cyclin-dependent kinases (CDKs; olive), inhibitor of apoptosis (IAP) proteins           
(purple); and isocitrate dehydrogenases (IDH1/2; peach). Other targets of developmental          
drugs whose efficacy may be governed by driver genetic alterations (bottom) include poly             
(ADP-ribose) polymerase (PARP), histone deacetylases (HDACs), and histone        
methyltransferases (HMTs). Proteins with dashed borders (RAS, guanine exchange factors          
[GEFs], RAC, PTCH, SWI/SNF) represent key pathway or epigenetic effectors not yet            
directly targeted by drugs in development. ALK, anaplastic lymphoma kinase; BTK, Bruton's            
tyrosine kinase; EGFR, epidermal growth factor receptor; FAK, focal adhesion kinase; FGFR,            
fibroblast growth factor receptor; FLT3, FMS-related tyrosine kinase 3; PDGFR,          
platelet-derived growth factor receptor” (Figure taken from Garraway 8 ). 
 
Analysis of subcellular location of targets of these drugs showed that a bit less than               
half of the targets are located in the plasma membrane, one quarter is located in               
cytoplasm, one quarter is located in nucleus and just 7% is in extracellular space              
(Fig 3a). Analysis of targets’ functional annotation revealed that two largest groups            
of targets are enzymes (57%) and receptors (26%). Within the enzymes the largest             
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subfamily is tyrosine kinases, other prominent subfamilies include serine/threonine         
kinases, peptidases and epigenetic modulators. Within receptor subfamilies there         
are transmembrane receptors, ligand-dependent nuclear receptors and G-protein        
coupled receptors (Fig. 3b,c). 9 
 
 
Figure 3. Subcellular location and function of drug targets.  ( a )  Percentage of anticancer             
drug targets belonging different subcellular locations ( b ) drug targets function families           
breakdown ( c )  detailed functional classification for enzymes and receptors families (Figure           
taken from Sun et al. 9 ) 
 
Comparison of list of consensus 33 cancer driver genes from Cancer Gene            
Census 12 with list of 109 protein targets of FDA approved drugs showed that there              
are only 30 proteins in overlap between the two sets. 10,13 Therefore there is a huge               
potential in extending the spectrum of targeted drugs covering the whole range of             
cancer vulnerabilities including oncogene and non-oncogene dependencies. 14 
 
Most tumors usually have defects in more than one signalling pathway. Therefore, a             
dual-targeting or multitargeting might be a rational strategy to eliminate cancer cells            
efficiently 1 (Figure 4 shows different hallmarks of tumor progression and classes of            
targeted therapies that interfere with these hallmarks 15 ). Also combining drugs that           
interfere with “parallel” pathways can limit the emergence of drug resistance which            
is critical since drug resistance results in cancer relapse. Let’s review resistance to             
treatment in the next subsection. 
 
17 
 
Figure 4. Therapeutic Targeting of the Hallmarks of Cancer (Figure taken from Hanahan &              
Weinberg 15 ) Drug classes are matched with hallmarks they interfere with. 
1.2.3 Resistance to treatment 
Resistance represents major obstacles to successful cancer therapy. Resistance         
occurs to both chemotherapies and to targeted therapies. 16,17 
Drug resistance can be divided into two categories -- intrinsic or acquired. Intrinsic             
resistance indicates that before receiving drug therapy, resistance-mediating factors         
pre-exist in the tumour cells which makes the therapy ineffective. Acquired drug            
resistance can develop during treatment of tumours that were initially sensitive and            
can be caused by mutations arising during treatment, or through various other            
adaptive responses, such as increased expression of the drug target and activation            
of alternative compensatory signalling pathways. 16 
 
Mechanisms of resistance to cytotoxic chemotherapies and targeted drugs largely          
overlap. 
Holohan et al. 16 classifies all mechanisms implicated in resistance into 6 groups: (1)             
drug transport and metabolism which includes drug efflux and drug inactivation/lack           
of activation, (2) alterations in drug targets, which is a major cause of resistance for               
targeted therapies; alteration can be in a form of mutation that alters drug-target             
binding site in the protein or in a form of protein overexpression, (3) DNA damage               
repair which is a typical mechanism of resistance to DNA-damaging agents, (4)            
downstream resistance mechanisms such as deregulation of apoptosis or         
18 
autophagy, (5) resistance-promoting adaptive responses, this group of mechanisms         
include activation of prosurvival signalling, oncogenic bypass and pathway         
redundancy and epithelial-mesenchymal transition, (6) tumor microenvironment       
protection via integrins, cytokines and growth factors. 
 
In addition to these mechanisms intra-tumour heterogeneity can also contribute to           
development of resistance -- since tumor can have different cell subpopulations           
with distinct genomic alterations (i.e. some fraction of cells can be sensitive to             
treatment while another fraction can be resistant) drug resistance can arise through            
therapy-induced selection of a resistant minor subpopulation of cells that were           
present in the original tumor. 16,18 
 
The use of high-throughput sensitivity and molecular screening techniques can help           
to identify resistance mechanisms and allow patient stratification with respect to the            
treatment response i.e. predict events of sensitivity or resistance. Let’s review           
different types of drug sensitivity testing in the next section. 
1.3 Drug sensitivity testing 
Clinical response to anticancer therapeutics is heterogeneous, which is a major           
barrier to effective cancer care. An ability to more accurately predict response            
before choice of treatment would improve patient response rates and reduce           
unnecessary treatments. 
In order to predict treatment response it’s necessary to combine two kinds of data --               
tumor molecular information and drug response information. Since it’s difficult to           
generate this data for a large number of patient, alternative model systems are used              
for this end (Fig. 5). 
 
Figure 5. Cancer models. “Figure shows schematically the timeline of development of            
cancer models and cancer therapies to address the challenges in personalized medicine”            
(Figure taken from Kalamara et al. 19 ) 
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1.3.1 Cancer preclinical models 
Model systems for studying drug response can be broadly divided into  in vitro ,  in              
vivo and  ex vivo types. 
In vitro. Cancer cell lines are the most popular amongst all preclinical cancer             
models. They can be relatively easily grown in the laboratory and therefore can be              
subject to multiple experiments, including multi-omics molecular characterization as         
well as treatment with many drugs or drug combinations. Connection of molecular            
characterization and treatment provide data for studying pharmacogenomic        
associations. A major drawback of cell line models is the lack of tumor             
microenvironment and of intrinsic heterogeneity compared to the original tumor. 20,19 
Patient-derived organoids (PDO) or organotypic cultures, three-dimensional cell        
cultures derived from a patient's tumor are considered to be a better  in vitro              
model. 21,22 They more accurately represent the intrinsic environment of the original           
tumor since they can include multiple cell types and self-organize into tissue-like            
structures. Drug response-genomic associations in organoids are more similar to          
those of real tumors compared to cell lines . A  main drawback of PDO models is the                
difficulty to maintain them in long-term cultures. 19 
 
In vivo. Mouse-based  in vivo models are a valuable tool for preclinical evaluation of              
novel therapeutic strategies in cancer. Patient-derived tumor xenograft (PDX)         
models 9,23 are obtained by direct implants of patient's tumor cells or tissue            
fragments in immunodeficient mice. PDX models can recapitulate the heterogeneity          
and intrinsic drug sensitivity of the primary tumor. However, they are a limited model              
of tumors  in vivo , in particular of the interaction of the tumor with the immune               
system. 19 
Another type of mouse models is genetically engineered mouse (GEM) model.           
GEM is a mouse whose genome has been edited by genetic engineering            
techniques to initiate tumorigenesis. GEM models harbor significant genetic         
heterogeneity although they do not reflect the complex heterogeneity of a human            
tumor. The difference between mouse and human organism is the main obstacle for             
immuno-oncology drug discovery studies. This gap is filled by “humanized” PDX           
models which are additionally engrafted with human immune cells. 19 Main          
challenges for both PDX and GEM are time required to generate tumor material and              
test the treatment regimen which can take 4-8 month, variability in engraftment rate,             
and higher costs compared to the other model systems. 22,24 
 
Ex vivo.  Ex vivo  model systems involve taking a sample out of the organism or               
patient and studying it under more controlled conditions than in vivo. Obtained            
samples are typically not cultured for long periods, so they still retain the original              
characteristics. 19 This approach is becoming routine in investigations of basic          
biological mechanisms in haematological malignancies and in drug discovery. 25,26 
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1.3.2 Cell line drug screening 
The majority of pharmacogenomics studies performed up to date is based on            
cancer cell line drug screens. Cell line drug screening is the process of screening              
anti-cancer compounds against a panel of cell lines. Typically a single experiment            
(one drug-one cell line) includes several probes for testing different concentrations           
of a drug, in each probe cell line is incubated with a drug and then cell viability (i.e.                  
amount of survived cells) is assessed via viability assays that measure either            
metabolic (i.e. number of ATP molecules) or DNA content. 27 
 
Figure 6. Exemplary dose-response curves from two drugs that have different potency and             
efficacy. 
 
Information from dose-response curves (Fig. 6) can be summarised using standard           
drug response metrics as half-maximal inhibitory concentration (IC 50 ) which is a           
measure of drug potency and area under the dose–response curve (AUC) that            
takes into account drug potency and efficacy. 
 
Although cell lines is the most widely used model in pharmacogenomics it’s            
important to acknowledge that there are differences between cell lines and real            
tumors. Cell lines acquire molecular changes in the culture (genetic, expression           
changes), they no longer retain tumor heterogeneity, they have higher growth rates,            
unlike real tumors cell lines are 2D and lack tumor microenvironment. 22,28 
1.4 Main pharmacogenomics datasets 
Several large-scale datasets have been generated in order to link genomic and            
pharmacologic profiles of cell lines (Fig. 7). The first one was NCI-60 panel, 29             
established in the late 1980s, which utilized 60 cancer cell lines and aimed to              
identify and characterize novel compounds with tumor-killing properties. These cell          
lines were molecularly profiled to identify biomarkers of response, providing the first            
resource for cancer pharmacogenomics. Since then, cell line screening has          
become a popular platform for cancer research and screens with larger number of             
cell lines followed. 
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Figure 7. Organisation of large scale pharmacogenomics profiling. Typical         
pharmacogenomics study consists of two parts -- cell line molecular profiling and drug             
sensitivity profiling. (Figure taken from Haibe-Kains 30 ) 
 
Recently, data on several large-scale pharmacogenomics became publicly        
available (see Table 3).  
 
Table 3. List of pharmacogenomics datasets with corresponding cell lines and drug            
numbers.  
Dataset # of cell lines # of drugs 
CCLE 31 505 24 
CTRP 32 860 481 
GDSC 34 1000 265 
gCSI 36 410 16 
NIBR 
PDXE 37 
23-38 xenografts per drug 62 
 
In the Cancer Cell Line Encyclopedia (CCLE) 31 project ∼1000 human cancer cell            
lines were collected and molecularly characterized, including gene expression,         
copy number alteration, and somatic mutation profiling. The project released the           
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drug sensitivity profiles of 24 anticancer drugs across 504 cell lines. Analogously to             
the CCLE project, the Cancer Therapeutics Response Portal (CTRP) 32 screened          
around 500 compounds and some of their combinations on the CCLE cell lines. 33 
The Genomics of Drug Sensitivity in Cancer (GDSC) 34 project profiled the           
sensitivity of about 1000 cell lines to 250 compounds and identified many genetic             
alterations associated with drug efficacy . The project investigators also compared          
genomic information on 11 289 tumors from TCGA with profiled cancer cell lines             
and identified shared ‘cancer functional events’ (CFEs), key molecular aberrations,          
shared between cell line and tumor data. Drug response information from cell lines             
with similar CFEs to the tumor of interest were used to predict the response to a                
given drug therapy. Mutation and copy number information were the most predictive            
of drug response in specific tissue types while gene expression was most            
informative for pan-cancer predictions. 35 
The Genentech Cell Line Screening Initiative (gCSI) 36 screened 16 compounds on           
410 cell lines, these compounds and some of the cell lines were previously tested              
by CCLE and GDSC projects.  
As we discussed, mouse models can better recapitulate the drug response of real             
tumors. However due to higher costs and more laborious procedures large-scale           
pharmacogenomics studies performed on mice are less abundant. Novartis         
Institutes of Biomedical Research PDX Encyclopedia (NIBR PDXE) 37 established         
∼1000 patient-derived tumor xenograft (PDX) models representing 16 different         
cancer types with a diverse set of mutation profiles. Around 200 of these PDX              
models were screened  in vivo  to assess the responses to 62 compounds.  
 
Altogether these pharmacogenomics studies provided rich resources for improving         
our understanding of cellular response to drugs, and generated data allowed to            
develop prediction algorithms that match drug response with genomic features.          
Let’s review various modelling approaches that have been applied to          
pharmacogenomics data in the next section. 
1.5 Existing modelling approaches and DREAM      
challenge 
1.5.1 Existing modelling approaches 
Various machine learning approaches can be used for drug response prediction,           
ranging from linear models that have advantage of good interpretability to non-linear            
models that usually show better performance but worse interpretability. 
 
Depending on outcome variable all models can be divided into two classes --             
regression and classification models. Regression models predict continuous        
outcome e.g. IC 50 or AUC numerical values, classification models predict          
categorical outcome, which is often binary in drug response prediction problems           
e.g. “sensitivity” vs. “resistance”. 
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Typically drug-response prediction problems have a “bottleneck of data         
dimensionality” 33 -- molecular data have high-dimensionality (just one molecular         
layer gives ~20000 of features), while number of samples that have drug response             
information is relatively small (100-1000 samples). Therefore quite often modelling          
approaches include certain feature selection (dimensionality reduction) strategies.        
Feature selection can be done prior to model fitting e.g. by selecting features that              
correlated with outcome, selecting features with high variance or selecting features           
using prior literature knowledge. Also feature selection can be a part of model fitting              
process e.g. as in case of regularized methods (see section 1.7). 
 
A number of different machine learning methods has been applied to drug response             
prediction problem (see Table 4), the most widely used were regularized regression            
methods (lasso, elastic net, ridge regression), kernel-based methods (e.g. SVM)          
and ensemble methods (e.g. Random Forest). 
 
Table 4. Spectrum of machine learning methods applied to drug response prediction            
problem. Adapted from Ali & Aittokallio. 38  
Class Method Example applications 
 
Regularized 
linear 
regression 
Lasso 
regression 
Fang et al. 39  applied lasso regression to CCLE 
data using iterative approach for feature 
selection. 
Ridge 
regression 
“Geeleher et al. (2014) 40  and Geeleher et al. 
(2017) 41  applied ridge regression model to 
predict drug responses in GDSC cell lines, and 
inferred marker panels for predicting 
comprehensive drug response profiles in patient 
tumors in the TCGA dataset.” 
Elastic net 
regression 
“Jang et al. 42  found elastic net regression as one 
of the best-performing modeling strategies for 
drug response prediction in CCLE and GDSC 
cancer cell lines.” Falgreen et al. 43  used elastic 
net to predict resistance in diffuse large B-cell 
lymphoma patients treated with 
cyclophosphamide, doxorubicin and vincristine. 
Elastic net regression was used in a number of 
other studies -- Barretina et al. 31 , Iorio et al. 34 , 
Aben at al. 44 
Kernel-based SVM 
(support vector 
machines) 
Dong et al. 45  used SVM classification model to 
predict drug sensitivity for several drugs using 
baseline gene expression of cell line panels from 
CCLE and GDSC studies. Other applications 
include Jang et al. 42  and Hejase & Chan. 46 
BEMKL 
(Bayesian 
Kernelized regression model for drug response 
prediction based on data integration across 
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efficient multiple 
kernel learning) 
multiple omics profiles, through multi-task, 
multiple kernel learning was the best performing 
method in the DREAM challenge (Costello et 
al. 47 ) In a follow-up work by Ali et al. 48  this 
method was applied to  NCI-60 cell line panel. 
cwKBMF 
(component-wis
e kernelized 
Bayesian matrix 
factorization) 
Ammad-ud-din et al. 49,50  proposed a model that 
utilizes cell line information along with the drug 
chemical properties as an additional information 
source through selective data integration. Model 
was applied to GDSC and CTRP cancer cell line 
data and to in-house AML cell lines data. 38 
Ensemble Random Forest “Riddick et al. 51  built an ensemble regression 
model using random forest (RF) for drug 
sensitivity prediction in NCI-60 cell line panel. 
The model was also used to create 
drug-specific gene expression signatures and 
identify core cell lines associated with each 
drug’s response.” Other applications of RF 
include, e.g., Iorio et al. 34 , Nguyen et al. 52 , and 
Rahman et al. 53 
Neural 
networks 
“Classical” 
Neural 
Networks 
Menden et al. 54  used a neural networks 
algorithm to train models that co-utilise cell line 
genomic and drug physicochemical and 
structural features. 
Deep learning Recently a number of approaches based on 
deep learning was proposed e.g. Ding et al. 55 , 
Chang et al. 56 
 
1.5.2 DREAM challenge 
Despite the big number of various approaches applied to drug response prediction            
problem, different approaches are rarely being compared in terms of prediction           
accuracy in a systematic manner. The DREAM challenge 47 organized by          
consortium of Dialogue on Reverse Engineering Assessment and Methods         
(DREAM) provided an opportunity for such systematic comparison.  
The task of the challenge was to predict drug response in the panel of breast cancer                
cell lines (18 lines were in the test set, and drug response data for 35 lines was                 
available for training) profiled with 28 drugs. Available molecular data included           
genomics, transcriptomics, methylation and protein information. In this challenge 44          
modelling approaches were evaluated on their performance. 
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This DREAM challenge reported a number of useful observations 33 : 
(1) all top solutions utilized nonlinear methods 
(2) predictive performance benefited from prior knowledge of biological pathways 
(3) gene expression data provided the highest predictive performance among all           
molecular data types; also performance could be further improved by including           
other data types 
(4) integrating predictions from independent methods (via an ensemble model          
consisted of different independent models) produced the most robust results since           
different methods had complementary advantages in examining different aspects of          
the data. 
1.6 Problem of inconsistency between     
pharmacogenomics datasets 
 
One of the common strategies for evaluating accuracy of drug response models is             
to fit a model using data from one dataset, and then assess model accuracy on               
another dataset. When Papillon-Cavanagh and his colleagues 57 tried to use this           
strategy, namely training models on GDSC and then validating them on CCLE, they             
realized that the validation in terms of model accuracy worked only for a small              
subset of drugs that are in common between two datasets.  
 
Subsequent investigation performed by Haibe-Kains et al. 58 discovered        
inconsistencies between drug response data published in GDSC and CCLE          
studies. These inconsistencies had negative impact on the development of drug           
response models. 59 The study triggered a number of subsequent efforts to assess            
the consistency between the two pharmacogenomics datasets which resulted in the           
number of papers arguing either pro or against consistency. 60-64 These studies           
suggest different methodological strategies one can use to assess the consistency           
and discussed possible sources of discrepancies in the data. 59,65 Also this           
discussion facilitated the development of resources that provide access to many           
different cell line pharmacogenomics datasets in a unified manner. 66,67 
 
Meanwhile Genentech published a comparative study 36 using their own data (gCSI           
dataset) as reference and observed that their drug sensitivity data was more similar             
to CCLE (which used the same pharmacological assay) than to GDSC. This study             
evaluated different aspects of the screening protocols that are relevant for           
measuring drug response, including the readout of cell viability, seeding density, and            
cell culture media conditions. The authors discovered that differences in media           
conditions and seeding density contributed to inconsistencies between studies, and          
that metabolic and DNA-content drug sensitivity assays exhibit different levels of           
noise. 59  
 
Currently the consensus is that molecular profiles (e.g. expression profiles) of           
CCLE and GDSC show consistency while inconsistency is observed for drug           
sensitivity measures between two datasets. The main sources of this inconsistency           
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are intrinsic noise of pharmacological profiling, differences in experimental protocols          
and differences in curve fitting. The standardisation on the level of experimental            
procedures as well as in data analysis will help to reduce inconsistency in the future               
studies which should improve identification of robust drug response biomarkers and           
developing accurate drug response models. 59,65 
1.7 Basic machine learning concepts, Feature Selection       
and description of used methods (elastic net, SVM,        
Random Forest) 
1.7.1 Basics 
 
Machine learning, a collection of data-analytical methods aimed at building          
predictive models from multi-dimensional datasets, plays an increasingly important         
role in modern biological research. 68 Let’s now review basic concepts and principles            
of machine learning. 
 
All machine learning methods can be broadly divided into two classes -- supervised             
and unsupervised methods. The main distinction is that supervised methods deal           
with labelled samples in a way that they learn how to predict correct label from the                
sample’s features (Fig. 8) while unsupervised methods analyse samples without          
taking label information into account. Although we mainly focus here on supervised            
methods (since our main interest to predict a certain kind of labels -- drug response)               
unsupervised learning, including standard clustering techniques, can provide some         
basis for generating prediction models, particularly unsupervised methods are         
helpful in data selection and visualization. 69 
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Figure 8. A canonical example of a machine learning application. “A training set of DNA               
sequences is provided as input to a learning procedure, along with binary labels indicating              
whether each sequence is centred on a transcription start site (TSS) or not. The learning               
algorithm produces a model that can then be subsequently used, in conjunction with a              
prediction algorithm, to assign predicted labels (such as 'TSS' or 'not TSS') to unlabelled test               
sequences. In the figure, the red–blue gradient might represent, for example, the scores of              
various motif models (one per column) against the DNA sequence.” (Figure taken from             
Libbrecht & Noble 70 ) 
 
Supervised problems can be separated into classification and regression problems.          
When labels are categorical the problem is a classification one, labels on            
continuous scale constitute a regression problem. 
 
Let’s consider typical steps of supervised machine learning (ML) workflow. 
1. Getting data and preprocessing . We usually get data as a matrix (see Fig. 8)              
where each row contains data for certain sample and each column contains            
data for certain feature (or vice versa). In biological problems features can            
include one or several types of molecular data e.g. expression data, copy            
number data, methylation, mutation statuses for a number of genes. One of            
the columns typically contain labels. Preprocessing can include necessary         
transformation of features and dealing with missing data (e.g imputation of           
missing values or exclusion of samples that contain missing values). Then a            
subset of data, training set, is used in the next step. 
2. Training a model . During training (or “fitting”) process ML algorithm is finding            
the optimal set of model parameters that translate features in the training set             
into accurate predictions of the labels.  
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3. Testing a model . When model is ready we can apply it to test data (part of                
data that was not used for training) and then by comparing predicted labels             
with true labels we can estimate accuracy of our model. 
 
An essential goal of model training is to build a model that is generalizable beyond               
the data used for fitting the model, i.e. a model that can make accurate predictions               
on a new input data. That’s why it’s important to divide the full data available for                
training into two sets -- training and test sets (some strategies involve division into              
three sets -- training, test, and validation). This division allows to assess            
generalizability of the model fitted on training set by checking its accuracy on test              
set. In cases when model explains the data in training set accurately but accuracy              
on test set is substantially lower one may conclude that overfitting has occurred,             
which means that model is “over-fitted” to the data in training set and is not               
generalizable. Therefore division into 2 or 3 sets gives a way to select more              
accurate model and estimate its accuracy in unbiased way. 69 
1.7.2 Feature selection 
As we have already discussed in the section 1.5, data used for modelling often has               
a number of features that by several orders of magnitude higher that number of              
samples. High dimensionality of the data can contribute to the problem of overfitting             
and often increases computational time for model fitting. There are several methods            
to perform a feature selection from high-dimensional data which can be divided into             
three classes: filter, wrapper and embedded methods. 
Filter methods evaluate the relevance of the predictors prior to model fitting            
procedure. Features are evaluated individually i.e. in a univariate manner on the            
basis of association with outcome. For example in regression problems, one can            
assess correlation between individual features and outcome and select for          
modelling only those features that have a correlation coefficient higher than certain            
threshold. 71 
Wrapper methods compare multiple models using procedures that add and/or          
remove predictors to find the optimal combination that results in maximal model            
performance. Essentially, wrapper methods are search algorithms that use different          
sets of predictors as the inputs and utilize model performance as the output to be               
optimized. Examples of wrapper methods include recursive feature elimination,         
genetic algorithms, and simulated annealing. 71 
Embedded methods are group of techniques that perform model selection as a part             
model construction process. Thus in these methods predictor search algorithm is           
coupled with a parameter estimation and they are optimized using a single objective             
function. 71 We will consider one of the most common type of embedded methods,             
regularized regression, in the next subsection. 
 
Throughout the work described in the thesis we mainly used filter-based feature            
selection i.e. we assessed relationship between an outcome and each feature           
independently. For this assessment two functions from caret package 75 were used:           
anovaScores function for ranking features in classification tasks, and gamScores          
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function for ranking features in regression tasks. Function anovaScores treats the           
outcome as the independent variable and the predictor as the outcome. In this way,              
the null hypothesis is that the mean predictor values are equal across the different              
classes. For regression, gamScores fits a smoothing spline in the predictor to the             
outcome using a generalized additive model and tests to see if there is any              
functional relationship between the two. In each function the p-value is used as the              
score. 76 
1.7.3 ML Methods 
Here we will describe the main ideas behind the three groups of machine learning              
algorithms that we used throughout the study: regularized regression, support          
vector machines and random forest.  
 
Regularized regression 
First let’s introduce linear regression which provides a foundation for regularised           
regression. In linear regression approach we model the relationship between the           
variable we want to explain/predict (dependent variable), and the variables we want            
to use for prediction (independent variables also called covariates) in the following            
way: 
                                                                 (1)N (0, )y i = β x  ; ε0 + ∑
p
j=1
β j ij + εi  ~
 
σ2  
y i is the i th value of outcome variable, x ij is the i th value of j th predictor (x j ), 𝛽 j is the regression                     
coefficient for predictor x j , n is the total number of samples and p is the total number of                  
predictors. 𝜀 is error which is normally distributed with the 0 mean and variance .σ2  
 
In this way we would like to find such values for coefficients that our outcome            β j    
variable is equal to the linear combination of independent variables . In y i           x∑
p
j=1
β j ij   
other words we would like to optimize (minimize) our objective function, the sum of              
squared errors (SSE): 
SES = ∑
n
i=i
y β  
|
|
|
|
i − ∑
p
j=1
xij j
 |
|
|
|
2
 (2)  
 
Regularized regression optimizes a sum of the linear regression objective function           
(sum of the squared errors, SSE, Equation 2) and convex penalty terms on             
coefficients. These penalties help to find coefficients of the optimal solution in            
high-dimensional space while preventing the regression procedure from overfitting         
the training data. 72  
 
One common penalty, called L1 or LASSO (least absolute shrinkage and selection            
operator) shrinkage, limits the sum of absolute values of all coefficients (Equation            
3). LASSO regression achieves feature selection by setting most coefficients to           
zero and leaving the coefficients of essential variables as the only nonzero            
coefficients. 72  
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here 𝜆 is a parameter that controls strength of the L1 penalty. 
 
Another common penalty, called L2 or ridge shrinkage, limits the sum of squares of              
all coefficients (Equation 4). Ridge regression assigns nonzero coefficients to most           
variables and therefore does not perform feature selection. Ridge regression can           
achieve better prediction accuracy than LASSO when the features are highly           
collinear. 72 
       SSEL2 = ∑
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y β  
|
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β j
2   (4)  
here 𝜆 is a parameter that controls strength of the L2 penalty. 
 
Elastic net regression combines the advantage of LASSO and ridge regressions.           
Elastic net optimizes the sum of the objective function and the two penalties             
(Equation 5). The penalty weights (λ 1 and λ 2 ) can be selected via cross-validation             
procedure. 72 
   SSEEnet = ∑
n
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y β  
|
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2  (5)  
here 𝜆 1  and 𝜆 2   are parameters that control strength of the L1 and L2 penalties respectively. 
 
 
Support Vector Machines (SVM) 
The SVM algorithm is based on finding the hyperplane in high-dimensional space            
that maximizes the margin between classes in the training data (Fig. 9). Selecting             
hyperplane with the largest margin between classes maximizes the SVM's ability to            
predict the correct classification of previously unseen examples. The training          
examples that are closest to the hyperplane are called support vectors since they             
are supporting the margin. 73,74 
 
Computing SVM classifier means solving the following optimization problem (“soft          
margin” formulation): 
                                      (6)( w )minw,b 2
1 | |2 + C ∑
 
i
ξ i  
where ξ i = (1 (x )y )− f i i +  
Here  w is a weight vector (normal vector to hyperplane), f(x i ) is the class prediction               
for a data point i and y i is a class of point i (1 or -1). is a “hinge loss” function                ξ       
which penalizes points whose functional margin, f(x i )y i , is smaller than 1. is           ξ   
always non-negative. Since a distance between a point and hyperplane is inversely            
proportional to |w|, , by minimizing |w| we maximize separation between   d = |w|
f (x)         
points from two classes; term penalizes those data points that are close to a     C ∑
 
i
ξ i           
separating hyperplane. 
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Figure 9. Main concepts of SVMs “ ( a ) Two-dimensional expression profiles of lymphoblastic            
leukemia (ALL) and acute myeloid leukemia (AML) samples. Each dimension corresponds to            
the measured mRNA expression level of a given gene. The SVM's task is to assign a label to                  
the gene expression profile labeled 'Unknown'. ( b ) A separating hyperplane. Based upon this             
hyperplane, the inferred label of the 'Unknown' expression profile is 'ALL'. ( c ) A hyperplane in               
one dimension. The hyperplane is shown as a single black point. ( d ) A hyperplane in three                
dimensions. ( e ) Many possible separating hyperplanes. ( f ) The maximum-margin hyperplane.          
The three support vectors are circled. ( g ) A data set containing one error, indicated by arrow.                
( h ) A separating hyperplane with a soft margin. Error is indicated by arrow. ( i ) A nonseparable                
one-dimensional data set. ( j ) Separating previously nonseparable data. ( k ) A linearly           
nonseparable two-dimensional data set, which is linearly separable in four dimensions. ( l ) An             
SVM that has overfit a two-dimensional data set.” (Figure taken from Noble 74 ) 
 
An important concept to mention when discussing SVM method is kernel function            
(or kernel). Essentially kernel function can be seen as a similarity function that             
allows the SVM to perform classification in the two-dimensional space even when            
the data is one-dimensional (see Fig. 9 i,j). In general, kernel function projects the              
data from a low-dimensional space to a space of higher dimension. If one pick a               
good kernel function, then the data can become separable in the resulting higher             
dimensional space, even if it wasn’t separable in the lower dimensional space. 74 
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Random Forest (RF) 
Random forest is an ensemble method which utilizes many decision trees as            
individual learners. The idea of RF is based on bagging, an approach in which each               
learner is trained on a different bootstrap to increase their variation. 72  
Let’s consider the steps of random forest algorithm (given a dataset containing N             
samples and M features; see Fig. 10): 
1. Create n bootstrap samples (subsamples) from the original data. Typically n           
can range from 100 to several thousands. 
2. For each bootstrap sample, train a decision tree using m features (m is             
typically much smaller than M) at each node of the tree. The m features are               
selected randomly from the M features in the dataset and the decision tree             
will select the best split among the m features. 
3. A new test sample is classified by all the trees and the final decision is done                
by majority vote/averaging. 
 
 
 
Figure 10. Steps of Random Forest algorithm.  1. Random sampling. 2.Building the models.             
3. Bootstrap aggregating / majority vote. 
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1.8 Aims of thesis and thesis’ structure 
Сomputational prediction of drug response in cancer is a challenging problem.           
Despite the biological challenge of predicting complex cellular phenotype (which          
drug response is) using typically static multi-omics data (i.e. data that acquired            
before drug exposure) there are also data analysis challenges arising from           
complexity of the available data in terms of volume, noise and heterogeneity. 69            
Growing amount of pharmacogenomics data together with challenges gives us an           
opportunity to learn principles of creating accurate drug response prediction models,           
knowledge which is important in the emerging era of personalized medicine.  
 
The main goal of this thesis was to analyse the data from largest public              
pharmacogenomics screens in order to learn factors that determine accuracy of           
drug response prediction. This broad goal can be formulated as a set of more              
concrete study aims: 
1. Assess ways for improving consistency between independent       
pharmacogenomics datasets. 
2. Assess ways for increasing accuracy of drug prediction using some          
modifications over standard ML approaches and feature engineering. 
3. Analyse influence of ML algorithm selection on resulting prediction accuracy. 
4. Study how properties of training set influence prediction accuracy.         
Properties include: type of molecular data, number of features selected for           
modelling, number of samples, type of drug response metric. 
5. Compare accuracy of drug response prediction between cell lines and          
xenografts. 
6. Assess the feasibility of using models trained on cell line data for drug             
response prediction in xenografts and patients. 
 
Also in the process of working on main aims a number of auxiliary, more practical               
aims arose through collaborations: 
1. Analyse a drug-sensitivity screen performed on a panel of Burkitt cell lines. 
2. Analyse drug-sensitivity data on DKFZ-608 compound and create a model          
of drug response to the compound. 
3. Create an interactive visualisation that allow to see a group of samples from             
CTRP/GDSC screens on 2-dimensional plane, where x and y axes display           
drug response values for 2 different drugs of choice.  
 
The following chapters of the thesis present results accordingly to described study            
aims. Each chapter/analysis focuses on a certain problem or aspect of drug            
response modelling, see Fig. 11.  
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Figure 11. Sections of the Results chapter. 
 
In the first section I touch the problem of cross-set inconsistency and try to              
improve consistency of drug response data coming from different cell line datasets.            
In the second section we assess a number of methodological improvements           
(multi-task modelling instead of general single-task, combining training data for          
drugs that share the same target, addressing class imbalance) with respect to their             
ability to improve accuracy of prediction. In the third section we again try to learn               
which aspects of modelling affect the accuracy of prediction but this time we rather              
focus on the properties of training data i.e. sample size, type of molecular data, drug               
response metric etc. In the fourth section in addition to cell line we take into account                
xenograft data and compare models trained for the same drugs on cell line and on               
xenograft data. In the fifth section we assess our ability to predict treatment             
outcome in a number of patient cohorts using classification models trained on cell             
line data. Finally in the sixth section I will present two collaboration-studies in which              
we utilized drug response data analysis or modelling, and one interactive           
drug-response data visualisation example that we created. 
Results described in the chapters 4 and 5 are part of our manuscript “Drug              
response prediction in cell lines and xenografts” by Kurilov R, Haibe-Kains B and             
Brors B. 77 Results described in the section 7.3.1 of the chapter 7 are part of the                
paper “Drug-based perturbation screen uncovers synergistic drug combinations in         
Burkitt lymphoma” by Tomska K, Kurilov R. et al. 78 
 
 
 
 
 
 
35 
2 METHODS TO IMPROVE CROSS-SET     
CONSISTENCY 
2.1 Introduction 
As it was discussed in the general introduction (section 1.6) there is an observed              
inconsistency between pharmacogenomic data from different screens which        
presents an obstacle on the way of producing accurate models and/or identifying            
biomarkers of response using this data. Here we make an attempt to improve an              
agreement between pharmacogenomic data coming from different datasets. In the          
first part or our analysis (sections 2.2.1 and 2.3.1, drug response consistency) we             
focus on the agreement between drug sensitivity data alone and in the second part              
(sections 2.2.2 and 2.3.2, biomarkers’ consistency) we focus on the agreement           
between genomic-drug sensitivity data associations. 
2.2 Data and Methods 
2.2.1 Drug response consistency 
We focused on agreement between CTRP and GDSC datastets. Particularly we           
tried to improve consistency between two datasets for 19 drugs belonging to 6             
classes defined by drug’s target molecule (Table 5). Cell line genomics and drug             
response data were obtained via the PharmacoGx package (version 1.8.3). 66 As a            
drug response metric we used area under the dose-response curve, AUC (see Fig.             
20). 
 
Table 5. Drug targets with associated drugs. 
Drug target Common drugs (GDSC-CTRP) 
HDAC Tubastatin A,  Belinostat, Vorinostat, MS-275 (entinostat)  
EGFR Lapatinib, Erlotinib, Afatinib, Gefitinib  
MEK1, MEK2 (MAP2K1, MAP2K2)  Trametinib, Selumetinib  
BRAF PLX4720, Dabrafenib  
HSP90 SNX-2112, 17-AAG (tanespimycin)  
mTOR OSI-027, Rapamycin (sirolimus), BEZ235 (NVP-BEZ235),     
Temsirolimus, AZD803  
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We tested two approaches for improving the cross-set agreement: 
1)  Cell line filtering. We Identify cell lines whose drug response for certain drug is               
different from average drug response for drugs from the same class (drugs with the              
same target) within dataset, remove these cell lines within each dataset, and then             
compare drug response consistency for this drug between subsetted datasets. 
 
2)  GLDS correction. We correct drug response for general level of drug sensitivity             
(GLDS) using for correction drug response data from group of unrelated drugs            
(specific for a certain drug) and then compare drug response consistency for this             
drug between corrected datasets. The idea and motivation for GLDS correction is            
described in the study Geeleher et al. 79 
 
The algorithms for both methods: 
1) Cell line filtering 
Let’s assume that we have 3 drugs that inhibit the same molecular target, drug “1”,               
drug “2” and drug “3”, and we have drug response values for these drugs in two                
datasets, GDSC and CTRP (see Fig. 12). We also assume that the cell lines              
tested in both datasets are the same. 
1. calculate Spearman correlation between each pair of drugs (i.e. between          
drug “1” from GDSC and drug “1” from CTRP, between drug “2” from GDSC              
and drug “2” from CTRP etc.) before filtering 
2. scale each column (i.e. divide by column's standard deviation) 
3. calculate a column with mean values (across drugs “1”, “2”, “3”) for each             
dataset 
4. calculate difference between each drug column and mean column (in both           
datasets) 
5. from each column remove 10% of cell lines with highest difference 
6. calculate Spearman correlation between each pair of drugs after removal of           
cell lines (i.e. after filtering) 
7. calculate average correlation after 10 random removal of 10% (from original           
set) 
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Figure 12. Steps of the cell line filtering method. Rectangle bars represent vectors of cell               
lines’ drug response values. 
 
2) GLDS correction (Fig. 13a) 
1. for each drug within each dataset we defined a set of unrelated drugs based              
on drug response correlation (Spearman correlation <0.15) and drug class          
annotation. 
2. calculate correlation between a pair of drugs before correction 
3. subtract from each drug's column mean of all columns from unrelated drugs 
4. calculate correlation after correction 
2.2.2 Biomarkers’ consistency 
Here we  focused on biomarkers' consistency in two groups: 1) between GDSC,            
CTRP and NIBR PDXE 37 and 2) between GDSC, CTRP and gCSI, before and after              
GLDS correction.  
In the first group there were 6 drugs in overlap between 3 studies: 5-Fluorouracil              
(DNA), erlotinib (EGFR), gemcitabine (cytoskeleton), paclitaxel  ( - tubulin) ,      β   
tamoxifen (estrogen receptor), trametinib (MEK).  
In the second group there were 12 drugs in overlap between 3 studies: bortezomib              
(proteasome inhibitor) , crizotinib (ALK, ROS1), docetaxel (microtubules),       
doxorubicin (DNA intercalating agent), erlotinib (EGFR), GDC-0941 (PI3K),        
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gemcitabine (DNA synthesis inhibitor), lapatinib (EGFR), entinostat (HDAC1,        
HDAC3), paclitaxel  ( - tubulin) , sirolimus (mTOR), vorinostat (HDAC).β  
 
Cell line genomics and drug response data were obtained via the PharmacoGx            
package (version 1.8.3). 66 As a drug response metric we used area under curve             
(AUC). Xenograft genomics and raw drug response data for NIBR PDXE were            
taken from papers’ supplementary data. 37  
 
We applied GLDS correction method to improve biomarkers’ consistency in the           
following way. After defining the lists of unrelated drugs for each drug within each              
dataset, we calculated 2 models for each feature from each dataset (for each of 6               
drugs) - simple model and model with 10 additional predictors which are 10 principal              
components calculated from the matrix of drug responses of unrelated drugs (Fig.            
13b). 
  
Figure 13. Schematic overview of GLDS method. ( a ) simple variant of GLDS where we just               
use a vector of mean responses calculated from responses of unrelated drugs. ( b ) GLDS              
version for biomarker discovery which uses 10 PC calculated from responses of unrelated             
drugs as covariates in linear model. 
 
In order to assess consistency of biomarkers before and after GLDS we analysed             
regression coefficients (associated with biomarker).  
In each dataset we selected top N features with highest absolute value of             
regression coefficient and then looked at the number of overlapped selected           
features between 3 datasets before and after GLDS correction. 
Also we took a union of these features (from 3 datasets) and calculated Pearson              
correlation of regression coefficient vectors for features within this union between           
each pair of datasets (GDSC-CTRP, GDSC-NIBR or GDSC-gCSI, CTRP-NIBR or          
CTRP-gCSI) before and after GLDS correction.  
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2.3 Results 
2.3.1 Drug response consistency 
After applying the first method, simple cell line filtering, Spearman correlation           
between drug responses from GDSC and CTRP increased at least slightly almost            
in all cases (we did the test for 6 groups of drugs with the following targets: HDAC,                 
EGFR, MEK1/MEK2, BRAF, HSP90, mTOR, see Table 5). 
After applying the second method (GLDS correction, implemented as simple as           
subtracting average drug response, calculated on unrelated drugs, from the drug           
response of the drug of interest) cross-set correlation only decreased in all tested             
cases. Detailed results are shown in the Table 6. 
 
Table 6. Results of cell line filtering and GLDS correction. Cases where cross-set             
correlation increased after filtering are marked in red. 
target drug 
initial 
correlation 
Spearman 
corr. after 
filtering 
average 
correlation 
after 10 
random 
subsettings 
# of 
common 
lines 
# of lines 
after 
filtering 
Spearman
corr. after 
GLDS 
correction 
HDAC 
MS-275 0.36 0.5 0.33 165 136 0.23 
Belinostat 0.5 0.59 0.54 199 161 0.25 
Tubastatin A 0.31 0.37 0.3 222 176 0.25 
Vorinostat 0.57 0.64 0.59 390 314 0.23 
EGFR 
Lapatinib 0.1 0.16 0.05 146 114 -0.04 
Erlotinib 0.27 0.22 0.26 148 113 0.02 
Afatinib 0.05 0.09 0.03 383 322 -0.02 
Gefitinib 0.07 0.1 0.08 372 303 0.06 
MEK1,2 
Trametinib 0.51 0.48 0.53 192 158 0.09 
selumetinib 0.25 0.33 0.26 429 346 0.06 
BRAF 
PLX4720 0.35 0.38 0.34 433 353 0.32 
Dabrafenib 0.3 0.27 0.29 187 153 -0.06 
HSP90 
SNX-2112 0.56 0.58 0.3 430 349 0.23 
17-AAG 0.11 0.2 0.08 392 314 -0.16 
mTOR 
OSI-027 0.39 0.38 0.39 424 344 0.3 
Rapamycin 0.35 0.45 0.39 162 124 0.12 
BEZ235 0.21 0.29 0.19 279 228 -0.04 
Temsirolimus 0.13 0.22 0.17 201 158 0.12 
AZD8055 0.34 0.43 0.33 390 313 0.08 
 Average 0.30 0.35 0.3 292 236 0.11 
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2.3.2 Biomarkers’ consistency 
First, we analysed biomarkers’ consistency before and after GLDS correction          
between  GDSC, CTRP and NIBR datasets .  Results are shown in the Table 7.             
(cases where consistency after GLDS correction improved are marked in red) 
Only for one drug out of 6, Trametinib, we improved consistency between each pair              
of sets. For two drugs that target cytoskeleton – Gemcitabine and Paclitaxel, only             
NIBR-GDSC and NIBR-CTRP consistencies were improved (but not        
GDSC-CTRP). For Tamoxifen consistency between GDSC and CTRP seriously         
decreased after GLDS (marked in purple in the table).  
 
Table 7. Results of GLDS correction, for GDSC-CTRP-NIBR data, top 500 biomarkers.            
Cases where cross-set correlation between vectors of regression coefficient increased are           
marked in red. Cases where the number of common biomarkers (out of total 500) between 3                
datasets increased are marked in red too. 
GDSC - CTRP - 
NIBR (10 princ. 
comp.)  
# common 
biomarkers 
cor 
GDSC-CTRP cor GDSC-NIBR cor CTRP-NIBR 
fluorouracil 
before 21 0.71 0.10 0.013 
after 13 0.64 0.04 0.018 
erlotinib 
before 5 0.27 -0.27 -0.07 
after 2 0.28 -0.27 -0.08 
gemcitabine 
before 19 0.62 0.13 0.22 
after 17 0.57 0.19 0.25 
paclitaxel 
before 3 0.02 0.06 0.002 
after 4 -0.15 0.11 0.06 
tamoxifen 
before 6 0.18 0.07 -0.11 
after 4 0.014 0.14 -0.07 
trametinib 
before 2 0.60 -0.22 -0.07 
after 20 0.84 0.24 0.26 
 
Also we performed the same analysis using another cell line dataset (gCSI 36 ) as a              
third set i.e. GDSC-CTRP-gCSI, corresponding results are presented in the Table 8.            
Consistency improved at least slightly for 6 (out of 12 common) drugs between             
CTRP and gCSI set, only for two drugs between GDSC and and gCSI and only for                
one drug between GDSC and CTRP. 
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Table 8. Results of GLDS correction, GDSC-CTRP-gCSI data, for top 500 biomarkers.            
Cases where cross-set correlation between vectors of regression coefficient increased are           
marked in red. Cases where the number of common biomarkers (out of total 500) between 3                
datasets increased are marked in red too. 
GDSC - CTRP - 
gCSI (10 princ. 
comp.)  
# common 
biomarkers 
cor 
GDSC-CTRP cor GDSC-gCSI cor CTRP-gCSI 
bortezomib 
before 2 -0.40 0.07 0.23 
after 1 -0.14 0.11 0.12 
crizotinib 
before 2 -0.34 0.24 -0.11 
after 3 -0.39 0.31 -0.28 
docetaxel 
before 7 -0.48 -0.38 0.73 
after 10 -0.47 -0.36 0.76 
doxorubicin 
before 6 0.41 0.49 0.70 
after 8 0.34 0.35 0.72 
erlotinib 
before 2 0.40 0.66 0.65 
after 4 0.40 0.53 0.74 
GDC-0941 
before 6 0.54 0.47 0.44 
after 4 0.45 0.41 0.37 
gemcitabine 
before 18 0.67 0.68 0.71 
after 19 0.61 0.63 0.71 
lapatinib 
before 3 0.20 0.71 0.32 
after 4 0.48 0.70 0.56 
entinostat 
before 4 0.72 -0.55 -0.56 
after 4 0.54 -0.41 -0.61 
paclitaxel 
before 4 0.01 0.03 0.74 
after 3 -0.19 -0.18 0.77 
sirolimus 
(rapamycin) 
before 0 -0.31 -0.05 0.61 
after 0 -0.24 -0.11 0.62 
vorinostat 
before 13 0.77 0.75 0.75 
after 13 0.77 0.75 0.74 
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3 ATTEMPTS TO IMPROVE PREDICTION     
ACCURACY 
3.1 Introduction  
In this chapter we applied a number of various model training approaches with the              
common goal of improving the accuracy of predictions. In an attempt to co-utilise             
information from drugs that share the same target we tried to use regularised linear              
regression multi-task models (multi-task means that we train a group of drug            
response models jointly rather learn training each model independently) as well           
standard (single-task) models built on aggregated data (Fig. 19). In order to take into              
account interactions between genomic features we tried modelling with binary gene           
pairs (BGP) and multiplied features. Also we tried modelling with sample weighting            
giving higher weights to (usually) under-represented sensitive cell line samples.          
Finally we checked the effects of class imbalance and cross-set consistency on            
accuracy. 
3.2 Data and Methods 
In this group of analyses we used genomic and drug response data from two large 
datasets, CTRP and GDSC obtained via the PharmacoGx package (version 
1.8.3). 66  Particularly we focused on 19 drugs belonging 6 classes defined by drug’s 
target molecule (Table 5). As a drug response metric we used area under the 
dose-response curve, AUC (see Fig. 20).  
 
As modelling techniques we used regularized regression (lasso/ridge/elastic net) 
via glmnet package and Random Forest via caret + randomForest packages. 
Feature selection, model fitting and accuracy evaluation were performed using the 
following procedure: 
 
1. We select one dataset as a training set, and the other one as a test set. (e.g.                 
GDSC as a training set and CTRP as a test set).  
2. We perform feature selection using the gamScores function from caret          
package (see details in the section 1.7.2) on the training set. 
3. Then we fit the model with N selected features (with lowest p-values) on the              
training set data. Model’s hyperparameters are selected using        
cross-validation testing.  
4. We apply model to the test set, and calculate R 2 (explained variance,            
calculated as a square of correlation between predicted and observed          
outcomes) and RMSE (root mean squared error). 
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3.3 Results 
3.3.1 Multi-task glmnet models 
Multi-task learning is a class of machine learning approaches in which multiple            
learning tasks are solved at the same time. We hypothesized that we can gain              
some accuracy if we use multi-task approach in order to predict drug response for              
drugs that share the same molecular target.  
For testing this approach we used the functionality of glmnet package. Glmnet            
allows users to fit regularized regression models, i.e. it penalizes a number of             
variables with non-zero coefficients. In multi-task case information sharing between          
the tasks “involves which variables are selected, since when a variable is selected,             
a coefficient is fit for each response”. 80 We compared single-task (standard) and            
multi-task lasso models using all cell lines (pan-cancer modelling) and cell lines for             
each major tissue type separately (tissue-specific modelling). In both cases we           
haven’t found a consistent accuracy gain in multi-task models’ results (Fig. 14 and             
Fig. 15). 
 
 
Figure 14. Pan-cancer results of multi-task modelling in terms of R 2 . Lasso regression             
was used for modelling. T raining on GDSC dataset, validation on CTRP dataset . 
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Figure 15. Tissue-specific results of multi-task modelling for 6 tissues with the largest             
number of corresponding samples, R 2 . T raining on GDSC dataset, validation on CTRP            
dataset . Red bars represent multi-task models, blue bars represent single-task (standard)           
models. 
3.3.2 Modelling on aggregated data 
Here we combined training samples for drugs sharing the same molecular targets            
(see Fig. 16) and compared performance of models trained on the aggregated            
datasets with performance of models trained on single drug datasets.          
 
Figure 16. Visualization for the idea of modelling on aggregated data. In this example              
drug 1 and drug 2 are drugs which share the same target, and we combine their drug                 
responses in a single vector in order to build a common aggregated model. 
 
For modelling we used Random Forest modelling method. Results in terms of R 2             
are plotted in the Fig. 17. Similarly to multi-task modelling results here we don’t              
observe advantage of aggregated models over simple ones. 
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Figure 17. R 2 results for aggregated and standard approaches. Left picture -- training is              
done on GDSC set, testing is on CTRP set, right picture -- training is done on CTRP set,                  
testing is on GDSC set. 
3.3.3 Modelling with feature interactions 
Here we tried to improve model accuracy using feature engineering approach. We            
tested two types of engineered features based on combining information from a pair             
of expression features: 
1) Binary gene pairs (BGP): 
 
2) Multiplications of gene pairs: expA*expB 
 
In order to reduce total number of resulting features we used a number of feature               
sets filtered with different feature selection approaches: 
Total list of tested feature sets (“200 top cor” and “200 top var” denote here 200                
features with highest correlation with outcome or 200 most variant features) is            
presented in the Table 9: 
Table 9. List of tested feature sets 
Feature set # of features 
1. All features 20000 
2. 200 features with the highest correlation 
(with drug response) 
200 
3. 200 features with the highest variance 
(across all samples)  
200 
4. BGP features constructed from 200 
features with the highest correlation 
20000 
 
Comment: 200*200=40000 but since 
BGP(A,B) and BGP (B,A) contain 
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essentially the same information [BGP(A,B) 
=1- BGP (B,A)] the total number of used 
features here is 40000/2=20000  
5. 200 BGP features with highest correlation 
(with drug response) constructed from 200 
original features with the highest correlation 
200 
6. Multiplicated features constructed from 
200 features with the highest correlation 
 
20000 
 
Comment: 200*200=40000 but since 
exp(A)*exp(B) = exp(B)*exp(A) the total 
number of used features here is 
40000/2=20000  
7. 200 multiplicated features with highest 
correlation (with drug response) constructed 
from 200 original features with the highest 
correlation 
200 
8. BGP features constructed from 200 
features with the highest variance 
20000 
9. 200 BGP features with highest correlation 
(with drug response) constructed from 200 
original features with the highest variance 
200 
10. Multiplicated features constructed from 
200 features with the highest variance 
20000 
11. 200 multiplicated features with highest 
correlation (with drug response) constructed 
from 200 original features with the highest 
variance 
200 
 
We used lasso regression for modelling, R 2 results averaged across 19 tested            
drugs are showed in the Fig. 18. 
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Figure 18. R 2 results averaged across 19 tested drugs for each of the feature sets tested.                
Red bars correspond to non-engineered features, green bars correspond to BGP features,            
blue bars correspond to multiplicated features. Error bars depict ± one standard deviation.  
 
We can see that “multiplicated” features perform better than BGP, although just all             
features without feature selection or top 200 non-engineered (i.e. original) features           
selected by correlation perform as good as the best “multiplication” feature set. 
 
Also we performed the same analysis using Random Forest instead of lasso as a              
modelling method, R 2  results are shown in the Table 10. 
 
Table 10. R 2  results for random forest model based on different feature sets. 
Feature selection 
average R 2 across 19 drugs     
(GDSC → CTRP) average R 2  (CTRP → GDSC) 
200 top correlation 0.126 0.092 
200 top variance 0.119 0.035 
BGP (200 top cor) 200 top corr 0.132 0.129 
Multipl (200 top cor) 200 top corr 0.103 0.083 
 
In this case BGP performed better than multiplication features and even slightly            
better than top 200 highly correlated original features.  
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3.3.4 Modelling with weights 
There is a common pattern in the distribution of drug response/drug sensitivity            
values for a drug among the panel of tested cell lines -- usually sensitive samples               
are less represented compared to the resistant ones (this is especially the case for              
targeted therapies). Here, in order to improve accuracy of prediction, we tried to             
assign higher weights to under-represented sensitive samples using a number of           
different weighting schemes.  
We used lasso regression for modelling, results for different weighting schemes           
used are shown in the Table 11.  As we see weighting doesn’t produce visible              
increase in accuracy. 
Table 11. Different weighting schemes tested and corresponding average R 2  values. 
weighting 
average R 2 across 19 drugs     
(GDSC → CTRP) 
average R 2  
(CTRP → GDSC) 
no weighting 0.175 0.167 
w=1/AUC 0.175 0.163 
w=1 (AUC>0.5), w=2 (AUC<0.5) 0.176 0.168 
w=1 (AUC>0.5), w=10 (AUC<0.5) 0.178 0.161 
3.3.5 How class imbalance and cross-set inconsistency affect        
prediction accuracy 
We checked the effects of class imbalance and cross-set consistency (measured           
as cross-set AUC pearson correlation) on model performance (R 2 from lasso           
single-task models) for 19 drugs: 
● Class imbalance in GDSC set is negatively correlated with R 2 of models            
trained on GDSC set (-0.08) but surprisingly class imbalance in CTRP set is             
positively correlated with R 2  of models trained on CTRP set (0.21). 
● For both types of models, expectedly, there is a strong correlation between a             
cross-set AUC correlation and R 2 , 0.85 for models trained on GDSC set            
(and tested on CTRP set) and 0.91 for models trained on CTRP set (and              
tested on GDSC set). 
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4 TESTING INFLUENCE OF DIFFERENT     
ASPECTS OF MODEL TRAINING ON     
PREDICTION ACCURACY 
4.1 Introduction 
In this analysis we applied established machine learning methods to          
characterize how different model training strategies influence resulting performance.         
For this end we used data from largest comprehensive cell line drug screens             
performed up to date -- the Cancer Cell Line Encyclopedia 31 (CCLE), Cancer            
Therapeutic Portal 32 (CTRP) and Genomics of Drug Sensitivity in Cancer 34          
(GDSC). In the analysis we particularly focus on the properties of training set --              
feature type, response metric and number of features used in the model (Fig. 19).  
 
Figure 19. Overview of the analysis in the chapter 4. Modelling tasks (drug responses)               
and tested parameters (dataset, response metric, # of variables, feature type) are shown. 
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4.2 Data and Methods 
4.2.1 Data 
For modelling we used molecular (microarray expression, copy number,         
mutation information) and drug response data from 3 large cell line sensitivity            
screenings -- CCLE 31 , CTRP 32  and GDSC 34 . 
Cell line genomics and drug response data were obtained via the           
PharmacoGx package (version 1.8.3) 66 . Particularly for IC 50 (half maximal inhibitory          
concentration) and AUC (area under the drug response curve) data we used values             
recomputed by the package from the raw data -- “ic50_recomputed” and           
“auc_recomputed” (Fig. 20). In order to handle outlier values in IC 50 data we             
truncated the distribution at the 85th percentile. Also in this analysis in addition to              
AUC and IC 50 we used another metric -- viability at 1µM (µmol) extracted from the               
raw drug response data in each dataset (Fig. 20).  
  
Figure 20. Different cell line drug response metrics tested in the chapter 4. From the raw                
viability data we can calculate 3 drug response metrics -- IC 50 , AUC and viability at 1µM.  
 
4.2.2 Modelling 
For feature selection we employed filter-type feature selection function gamScores          
from caret package (see details in the section 1.7.2). After feature selection we fit              
the model with N selected features (with lowest p-values) on the training set data.  
 
As a modelling method we used SVM with Radial base function (svmRadial). In             
order to select hyperparameters (sigma and C(cost)), 30 different combinations of           
them are tested on training data using 10 fold cross-validation, and then the             
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combination that provides the lowest RMSE is used for fitting the final model.             
Hyperparameters ranges: sigma ⊂ [0.001;0.01], cost ⊂ [0.03;10000].  
As the accuracy measures we used R 2 (explained variance) and RMSE (root of             
mean squared error). 
 
Feature selection, model fitting and accuracy evaluation were performed using the 
following procedure (Fig. 21): 
1. We randomly split the data into training (70%) and test (30%) sets. 
2. We perform feature selection on the training set. 
3. Then we fit the model with N selected features (with lowest p-values) on              
the training set data. Model’s hyperparameters are selected using         
cross-validation testing.  
4. We apply model to the test set, and calculate R 2 (calculated as a square               
of correlation between predicted and observed outcomes) and RMSE. 
5. We repeat steps (1-4) ten times and get average R 2  and RMSE. 
 
 
Figure 21. Overview of the modelling process.  Main steps of modelling process are shown              
schematically: 1) Data split, 2) Feature selection, 3) Model fitting, 4) Accuracy evaluation. 
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4.3 Results 
We trained a number of models for seven drugs which are common            
between the 3 largest cell line datasets, CCLE, CTRP and GDSC: erlotinib (EGFR),             
paclitaxel (𝛽-tubulin), lapatinib (EGFR), PLX4720 (RAF), sorafenib (RAF), nutlin-3         
(MDM2) and nilotinib (ABL/BCR-ABL). Our drug-specific models differed in terms          
of: 
● Molecular feature types -- only expression vs. expression+copy        
number+mutation 
● Drug response metrics -- IC 50 , AUC, Viability_1µM 
● Number of variables in the model: 10, 50, 200, 500 
 
Results (for tests with all genomic features) in terms of R 2 are plotted in Fig. 22a.                
Each plot shows results for certain response metric combination, and within each            
plot there are results for each drug in each data set for the tests with 500 variables. 
 
 
a 
 
 
b                                                                                 c 
 
Figure 22. Accuracy results and analysis of common features ( a ) R 2 for 7 drugs across               
multiple testing conditions, number of variables=500. ( b ) Average (across three datasets) R 2            
values for each drug separately (for models with AUC metric). Error bars depict ± one               
standard deviation. ( c ) Number of common features out of top 500 features between 3              
datasets (CCLE, CTRP and GDSC) for each drug within each drug response metric. 
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We plotted predictions against observed values for each drug response metric for            
some drug/dataset combinations. In each plot the data points correspond to a test             
set from one particular (random) train/test sets split (Fig. 23). A dotted line shows              
where data points should lie in the ideal case of 100% correct predictions. In cases               
where the accuracy of prediction is satisfactory, the data points are grouped around             
the dotted line e.g. IC 50 , paclitaxel, CTRP (1 st row, 1 st column); AUC, nutlin-3, CTRP              
(2 nd row, 2 nd column); viability_1uM, paclitaxel, CCLE (3 rd row, 1 st column). In cases             
where prediction accuracy is low predicted and observed values are not correlated            
and therefore data points are not grouped around the dotted line. 
 
 
Figure 23. Observed vs. predicted values for drugs/datasets combinations that show           
either relatively high or extremely low R 2 accuracies within each drug response metric             
(IC 50 , AUC, viability at 1 µM ).  
 
We tested how prediction performance depends on the number of top variables            
(variables that have a strong correlation with outcome) selected for modelling and            
surprisingly found almost no correlation between R2 and number of variables,           
Pearson correlation across all tests = 0.02. Correlation coefficients for each drug            
individually vary between -0.08 and 0.11 
 
In these tests the average value of R 2 for modelling with all genomics data (0.153)               
was just slightly higher than for modelling with only expression data (0.145). While             
these differences are small for most of the drugs, for nutlin-3 and PLX4720 they are               
a bit more pronounced, which means that mutation status information contributes to            
the explained variance of drug response for these two drugs (Fig. 24). Below, we              
will discuss only models that are based on all genomic features (expression, copy             
number and mutation values).  
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Figure 24. Difference in average R 2 between models that use all genomic features and              
models that use only expression features for 7 drugs. 
 
We checked the number of common features out of selected top 500 features for              
each drug between 3 datasets (CCLE, CTRP and GDSC) within each drug            
response metric. The number of common features is relatively small for IC 50 metric             
(average = 10) and higher for AUC and viability at 1µM metrics (average = 47 and                
83 correspondingly, see Fig. 22c). Independently of response metric used there is            
almost no common features across paclitaxel models and across nutlin-3 models.  
 
Average R 2 values for each drug (for AUC models) are shown in the Fig. 22b. Five                
drugs -- PLX4720, paclitaxel, lapatinib, nutlin-3 and erlotinib had average R 2           
between 0.2 and 0.3 while Nilotinib and Sorafenib showed the lowest average            
predictability (R 2 =0.12 and 0.06 correspondingly). Average R 2 for each tissue          
separately are shown in the Fig. 25. 
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Figure 25. Average (across three datasets) R 2 values for each tissue and each drug              
separately  (for models with AUC metric and 500 variables). Error bars depict ± one standard               
deviation. 
 
We compared our results for CCLE dataset with elastic net modelling performance            
from the original CCLE study 31 and performance from integrated (combined)          
random forest method (CRF) 8 which was the second top performing method in the             
DREAM drug response prediction challenge 47 (We are comparing our results with           
the second top performing method instead of the first one simply because both             
methods have quite similar accuracy score in the original paper, wpc-index equals            
to 0.583 and 0.577 correspondingly, but the second method to our convenience was             
already tested on CCLE dataset with essentially the same accuracy metric that we             
are using in our analysis). Corresponding R 2  values are shown in the Table 12. 
 
Table 12. Comparison between prediction results from different methods in the form of             
R 2 values.  Dataset: CCLE. Response metric: AUC. Elastic net denotes the approach used in              
[31]. CRF-400 and CRF-20000 denote the approach used in [81]. SVM-500 denotes our             
results. Highest R 2  value for each drug is highlighted in boldface.  
Drug Elastic Net CRF-400 CRF-20000 SVM-500 (our results) 
erlotinib 0.09 0.16 0.18 0.22 
paclitaxel 0.36 0.30 0.30 0.31 
lapatinib 0.20 0.30 0.28 0.31 
nilotinib 0.58 0.30 0.30 0.16 
nutlin-3 0.01 0.08 0.10 0.003 
PLX4720 0.30 0.20 0.23 0.29 
sorafenib 0.07 0.17 0.22 0.12 
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5 TISSUE TYPE, DOUBLING TIME AND      
DRUG RESPONSE PREDICTION IN CELL     
LINES AND XENOGRAFTS 
5.1 Introduction 
In this analysis we compared the task of drug response prediction with the             
presumably easier prediction tasks, tissue type prediction and doubling time          
prediction, in terms of accuracy in order to see whether (and to which extent)              
potentially easier phenotypes than drug response can be predicted from genomic           
data. Additionally we compared the level of consistency for these results between            
cell lines and xenografts (Fig. 26).  
 
Figure 26. Overview of the analysis in the chapter 5. Modelling tasks (tissue type, doubling               
time and drug responses) and tested parameters (dataset, response metrics) are shown. 
5.2 Data and Methods 
5.2.1 Data 
For modelling we used molecular (microarray expression, copy number,         
mutation information) and drug response data from cell line sensitivity screen           
gCSI 36 and xenograft screen NIBR PDXE 37 . Cell line genomics data for gCSI            
dataset were taken from paper’s supplementary data 36 , drug response data for           
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gCSI was obtained via the PharmacoGx package (version 1.8.3). 66 Xenograft          
genomics and raw drug response data for NIBR PDXE were taken from papers’             
supplementary data. 37  
As a cell line drug response metric we used Area under drug response             
curve (AUC). For characterizing xenograft drug response we tested 4 different           
xenograft drug response metrics derived from raw drug response data (volume of            
the tumour during the treatment course at different days between day 0 and day              
21): tumour volume (at the day 21), integral response, slope of the tumor growth              
curve and differential slope (Fig. 27). 
 
 
Figure 27. Xenograft’s drug response metrics. Top: volume of the tumor, integral response;             
bottom: slope of the tumor growth curve, differential slope. 
5.2.2 Modelling 
For feature selection we employed filter-type feature selection functions gamScores          
(for regression tasks) and anovaScores (for classification tasks) from caret          
package (see details in the section 1.7.2). After feature selection we fit the model              
with N selected features (with lowest p-values) on the training set data.  
 
As a modelling method we used Random Forest for all modelling tasks except             
tissue classification for which xgBoost method was used. In order to select            
hyperparameters (e.g. mtry, number of predictors at each split, for RF), 30 different             
values for a hyperparameter are tested on training data using 10 fold            
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cross-validation, and then the value that provides the lowest RMSE (or AUROC for             
classification tasks) is used for fitting the final model. As the accuracy measures             
we used R 2 (explained variance) and RMSE (root of mean squared error) for             
regression tasks and percentage of correctly predicted samples for tissue          
classification tasks. 
 
Feature selection, model fitting and accuracy evaluation were performed using the 
following procedure (see Fig. 21): 
1. We randomly split the data into training (70%) and test (30%) sets. 
2. We perform feature selection on the training set. 
3. Then we fit the model with N selected features (with lowest p-values) on              
the training set data. Model’s hyperparameters are selected using         
cross-validation testing.  
4. We apply model to the test set, and calculate R 2 (explained variance,             
calculated as a square of correlation between predicted and observed          
outcomes) and RMSE. Alternatively for tissue classification the percentage         
of correctly predicted samples was calculated. 
5. We repeat steps (1-4) ten times and get average R 2 and RMSE (or              
percentage of correctly predicted samples for tissue classification tasks). 
5.3 Results 
We used the gCSI study 36 as in vitro training set, it is a high quality               
pharmacogenomic dataset reasonably consistent with CCLE and GDSC datasets.         
We used the NIBR PDXE 37 as in vivo validation set set since this is the only                
publicly available xenograft screen. We assessed 6 modelling tasks in each set --             
tissue type prediction, doubling time/slope of the tumor growth curve, erlotinib           
response (lung samples), gemcitabine response (pancreas samples), paclitaxel        
response (breast samples) and paclitaxel response (lung samples). Erlotinib,         
gemcitabine and paclitaxel were selected since these three drugs were tested in            
both gCSI and NIBR PDXE study. Tissue type and doubling time prediction tasks             
serve as a positive controls -- we assume that these phenotypes should be             
explained by genomics data better than drug response. 
For tissue prediction and doubling time/slope of the untreated tumor growth           
curve we used the top 400 features with lowest p-values. For drug response             
prediction (since sample sizes were much lower) we used just the top 100 features.  
In xenograft tissue prediction we had 5 tissue-classes with 27-50 samples per            
tissue. In cell line tissue prediction we tried modelling with 13 tissue-classes with             
10-68 samples per tissue and with 6 largest tissue-classes (each tissue had at             
least 23 samples). 
Prediction accuracy results for all prediction tasks are collected in the Table            
13. For tissue type prediction we report percentage of correctly predicted samples,            
for doubling time/slope and drug response prediction we report R 2 and concordance            
index values. 
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Table 13. Prediction accuracy for all prediction tasks.  We report here accuracy            
(percentage of correctly predicted samples) for tissue prediction, R 2 and concordance index            
for doubling time/slope and drug response prediction. 
 Tissue  
 
( Accuracy ) 
Doubling time 
(cell lines) / 
slope of the 
growth curve 
(xenografts) 
 
( R 2 , 
concordance 
index) 
Drug response ( R 2 , concordance index) 
drug resp. 
metric 
erlotinib  
(EGFR) 
Lung 
68 lines 
25 xen. 
gemcita
bine 
(DNA 
synth.) 
Pancrea
s 
26 lines 
32 xen. 
paclitaxel  
( -β  
tubulin) 
Breast 
29 lines 
38 xen. 
paclitaxel  
( -β  
tubulin) 
Lung 
68 lines 
23 xen. 
Average 
across 4 
drugs 
Cell lines 
(gCSI) 
329 samples 
Acc 6tissues = 0.79 
Acc 13tissues = 0.64 
0.17 
(0.64) 
 
 
AUC 0.06 
(0.57) 
 
 
0.13 
(0.61) 
 
 
0.14 
(0.66) 
 
 
0.08 
(0.57) 
 
 
0.10 
(0.60) 
Xenografts 
(NIBR) 
191 
samples, 
 
23-38 
samples per 
drug 
Acc= 0.89 0.19 
(0.60) 
Tumor 
volume 
0.34 
(0.69) 
0.04 
(0.49) 
0.08 
(0.53) 
0.46 
(0.74) 
0.23 
(0.61) 
Integral 
response  
0.18 
(0.59) 
0.03 
(0.50) 
0.08 
(0.57) 
0.09 
(0.47) 
0.10 
(0.53) 
slope 0.31 
(0.65) 
0.15 
(0.54) 
0.11 
(0.54) 
0.44 
(0.63) 
0.25 
(0.59) 
Differenti
al slope  
0.12 
(0.50) 
0.09 
(0.53) 
0.10 
(0.54) 
0.27 
(0.35) 
0.15 
(0.46) 
 
In addition to tissue prediction tests performed using all available cell line and             
xenografts we made a test with equal number of samples per tissue (16 samples in               
training set and 7 samples in test set). A heatmap for confusion table for the case of                 
cell line predictions is shown in the Fig. 28. 
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Figure 28. Confusion table heatmap for results of tissue classification in cell lines.  Row              
labels depict true classes, column labels depict predicted classes. Test set contained 7             
samples for each tissue, and modelling procedure was repeated 10 times, so for each tissue               
class 70 predictions were made. Color shows the number of predicted classes per each true               
class. 
 
While the differences in accuracies between tissue type prediction and doubling           
time/slope prediction are consistent for cell lines and xenografts, drug response           
prediction accuracies for the same drugs are not consistent between cell lines and             
xenografts. Particularly best performing drugs are gemcitabine and paclitaxel         
(breast) for cell lines and erlotinib, paclitaxel (lung) for xenografts. The level of             
consistency is also illustrated by the number of common features (between cell            
lines and xenografts) out of top features pre-selected for modelling. There are 31             
common features out of top 400 for tissue prediction between cell lines and             
xenografts, only 4 common features out of top 400 for doubling time/slope prediction             
and almost no common features out of top 100 for drug response prediction.  
 
In order to make the quality of prediction across different regression prediction            
tasks visually accessible, we plotted observed versus predicted values for different           
prediction tasks. In each task the data points correspond to a test set from one               
particular (random) train/test sets split (Fig. 29a). 
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a 
 
 
b 
 
 
Figure 29. Observed vs. predicted plots ( a ) Observed vs. predicted values for different             
regression prediction tasks. ( b ) Observed vs. predicted values for [cell lines → xenografts]             
type of prediction and corresponding correlation coefficients, only data volume and slope            
response metrics are shown 
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Manual inspection of outlier cases from observed vs. predicted plots (Fig. 29a)            
shows that often a model’s inability to provide an accurate prediction for certain             
samples (outliers) is driven by under-representation of samples with similar          
molecular characteristics to these outliers in the training set.  
 
Also we tested how well the models trained on cell line data can explain drug               
response in xenografts. For that we 1) trained drug response models using cell line              
genomics and drug response data (AUC), 2) got model’s predictions using           
xenografts molecular data as inputs, 3) assessed the correlation of resulting           
predictions (in cell line AUC units) with actual xenografts drug response. We tried 2              
strategies with respect to training set composition -- training using all cell lines and              
training using only cell lines that match tissue type of corresponding set of xenograft              
samples. Results in terms of correlation coefficients as well as predicted vs.            
observed plots for this analysis (for the case where we used all cell lines for               
training) are shown in the Fig. 29b. 
Among four xenograft response metrics used in this study volume and slope are             
expected to be positively correlated with cell line AUC while integral response            
(𝛥AUC) and differential slope are expected to be negatively correlated. For both            
training strategies (all cell lines or cell lines from one relevant tissue type) we              
managed to get predictions with the right sign of correlation coefficient (between            
predictions and observed drug response) and substantial absolute value for all drug            
response metrics only for erlotinib. Volume and slope metrics worked especially           
good in case of erlotinib with correlation about 0.5 in both cases.  
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6 PATIENT TREATMENT OUTCOME    
PREDICTION USING CLASSIFICATION   
MODELS TRAINED ON CELL LINES 
6.1 Introduction 
The next logical step after predicting drug response in xenografts is to try to predict               
drug response/treatment outcome in patients. Following the study design proposed          
in the Zhao et al. 82 we compared prediction performance of models trained on cell              
line data and applied to patient expression data. We used the same 3 patients set               
that were used in the paper 82 -- myeloma cohort treated with bortezomib            
(proteasome inhibitor), NSCLC cohort treated with erlotinib (EGFR inhibitor) and          
BRCA cohort treated with docetaxel (inhibits cell division by binding to           
microtubules), see Fig. 30. 
 
Figure 30. Overview of the analysis in the chapter 6. Modelling tasks (drug responses) and               
tested parameters (training dataset, response metric, response binarization strategy, tissue          
specificity) are shown. 
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6.2 Data and Methods 
6.2.1 Data 
For modelling we used molecular (microarray expression, copy number,         
mutation information) and drug response data from 4 large cell line sensitivity            
screenings -- CCLE 31 , CTRP 32 , GDSC 34 , gCSI 36 and one xenograft screen -- NIBR            
PDXE 37 . Genomics and cell line data were obtained either from projects web portals             
(CCLE, CTRP, GDSC) or from corresponding papers’ supplementary data (gCSI,          
NIBR PDXE). 
For cell lines’ drug response characterization we used IC 50 , AUC and           
viability at 1uM metrics. For xenograft’s response characterization we used          
xenograft response metrics from original publication 37 -- BestResponse and         
BestAverageResponse: 
“The response was determined by comparing tumor volume change at time t to its baseline:               
% tumor volume change = ΔVolt = 100% × ((Vt – Vinitial) / Vinitial). The BestResponse was                 
the minimum value of ΔVolt for t ≥ 10 d. For each time t, the average of ΔVolt from t = 0 to t                        
was also calculated. We defined the BestAvgResponse as the minimum value of this average              
for t ≥ 10 d.”  
 
For each [cell line dataset + patient cohort dataset] pair we combined two             
corresponding expression sets, and for each of such combined sets we trained a             
classification model on cell line data and tested predictive performance on patient            
data. 
In order to homogenise z-transformed expression data between cell line and patient            
sets we used ComBat method from “sva” package 83 . Cell line’s continuous           
response (IC 50 , AUC, viability at 1uM) and xenograft response (BestResponse,          
BestAverageResponse) were binarized to “sens” and “resist” labels. Treatment         
response labels for patient samples were obtained from paper’s 82 RData          
( http://compbio.cs.toronto.edu/cp2p/ ) and converted to “sens” and “resist” values,        
criteria for patient response binarization are listed in the Table 14. 
 
Table 14. Criteria for patient response binarization for each drug (from Zhao et al. 82 ). 
bortezomib “In the original paper, response was measured in terms of change in paraprotein: patients              
were classified as achieving complete response (CR, with 100% decrease in paraprotein),            
partial response (PR, 50% decrease), minimal response (MR, 25% decrease), no change            
(NC - absence of response, 2 measures of stable disease), or PD (25% increase in               
paraprotein), using European Group for Bone Marrow Transplantation criteria. We grouped           
MR, PR and CR patients into a response category; NC and PD patients into nonresponse.” 
erlotinib “Therapy response was defined as progression-free survival time of 2 or more months” 
docetaxel “Response to docetaxel neoadjuvant treatment was based on whether 25% of the tumor             
remained after four cycles of docetaxel” 
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6.2.2 Modelling 
For feature selection we employed filter-type feature selection function         
anovaScores from caret package (see details in the section 1.7.2). After feature            
selection we fit the model with N selected features (with lowest p-values) on the              
training set data.  
 
As a modelling method we used SVM with Radial base function (svmRadial). In             
order to select hyperparameters (sigma and C(cost)), 30 different combinations of           
them are tested on training data using 10 fold cross-validation, and then the             
combination that provides the lowest Balanced Accuracy (half sum of sensitivity           
and specificity) is used for fitting the final model. As the accuracy measures we              
used Balanced Accuracy and AUROC. 
 
Feature selection, model fitting and accuracy evaluation were performed using the 
following procedure : 
1. In each combined (cell-line + patient) dataset cell line samples are used as a 
training set (according to the state of tissue-specificity option either all or 
only cell lines from certain tissue are taken), patient samples -- as a test set. 
2. We perform feature selection using the anovaScores function on the training           
set. 
3. Then we fit the model with 200 selected features (with lowest p-values) on             
the training set data. Model’s hyperparameters are selected using         
cross-validation testing.  
4. We apply model to the test (patient) set, and calculate Balanced Accuracy            
and AUROC. 
6.3 Results 
For each of three drugs we tested several modelling options: 
1) Training dataset -- single: CTRP, GDSC, gCSI, NIBR, and combined:          
CTRP+ GDSC, CTRP+GDSC+gCSI and  CTRP+GDSC+gCSI+NIBR 
2) Response metric -- IC50, AUC, Viability_1uM (binarized) 
3) 2 types of binarization -- with and without intermediate class (grey zone) 
4) 2 types of sample selection -- pan-cancer (all cell lines) and tissue-specific            
(only cell lines that match tissue of corresponding patient set) 
 
Accuracy results for bortezomib turned out to be the lowest, with the balanced             
accuracy around 0.5 almost for all tested options, for erlotinib and docetaxel            
accuracy is generally higher. In the following tables we report average results for all              
tested options (Tables 15 -- 19). 
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Table 15. A combination of training options that produces the most accurate            
predictions for each of three drugs. 
drug dataset Response 
metric 
binarization Tissue 
specificity 
Balanced 
Accuracy 
AUROC 
bortezomib ctrp_gdsc
_gcsi 
auc With grey 
zone 
pan-cancer 0.53 0.455 
erlotinib gdsc auc With grey 
zone 
tissue-specific 0.80 0.786 
docetaxel ctrp_gdsc auc With grey 
zone 
pan-cancer 0.83 0.87 
 
Table 16. Average Balanced Accuracy for all  datasets for each drug. 
drug CTRP GDSC gCSI CTRP+ 
GDSC 
CTRP+ 
GDSC+gCSI 
CTRP+GDSC
+gCSI+NIBR 
bortezomib 0.48 0.47 0.47 0.49 0.49 -- 
erlotinib 0.52 0.52 0.41 0.505 0.53 0.53 
docetaxel 0.46 0.55 0.46 0.67 0.59 -- 
 
Table 17. Average Balanced Accuracy for all  response for each drug: 
drug IC50 AUC viability 
bortezomib 0.48 0.48 0.47 
erlotinib 0.47 0.57 0.47 
docetaxel 0.53 0.55 0.55 
 
Table 18. Average Balanced Accuracy for two  binarization options for each drug. 
drug Without “grey zone” With “grey zone” 
bortezomib 0.485 0.47 
erlotinib 0.47 0.52 
docetaxel 0.57 0.52 
 
Table 19. Average Balanced Accuracy for two tissue-specificity options for each drug. 
drug pan-cancer tissue-specific 
bortezomib 0.48 0.47 
erlotinib 0.53 0.46 
docetaxel 0.57 0.51 
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We also compared AUROC values between our best models (judged by AUROC)            
and best models from Zhao et al. study 82  (they used only GDSC data for training): 
 
Table 20. Area Under the ROC curve (AUROC) comparison between our models and             
models from Zhao et al. 
 
drug 
Our best models Best models from Zhao et al. 
IC50 AUC IC50 AUC 
bortezomib 0.60 0.57 0.62 0.68 
erlotinib 0.68 0.83 0.73 0.73 
docetaxel 0.88 0.89 0.91 0.91 
 
Some conclusions: 
● For different drugs different modelling options are beneficial. 
● Datasets. Best single datasets for Erlotinib are CTRP and GDSC, and for            
Docetaxel it is just GDSC, performances of combined datasets are similar           
to best single ones for Erlotinib but it’s significantly higher than performance            
of single best set for Docetaxel (CTRP+GDSC). 
● Response Metrics. AUC works better than two other metrics for Erlotinib, for            
Docetaxel AUC and viability show just marginally higher accuracy than          
IC50. 
● Grey zone. Average balanced accuracy for binarization with “grey zone” is           
higher than without for Erlotinib, but it is the opposite for Docetaxel. 
● Tissue specificity. For both erlotinib and docetaxel pan-cancer models show          
better performance than tissue-specific. 
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7 APPLIED EXAMPLES OF DRUG     
RESPONSE DATA ANALYSIS 
7.1 Introduction 
In this chapter we show some examples of modelling or other kinds of drug              
response association analyses performed in collaboration frameworks. In the first          
result’s subsection we discuss the analysis of the data from drug sensitivity screen             
of 42 blood cancer cell lines performed in the lab of Thorsten Zenz at NCT (National                
Center for Tumor Diseases, Heidelberg), the analysis consists of a descriptive part            
(drug-drug correlations, cell line-drug clustering, assessing synergisity of drug         
combinations) as well as a modelling part where we build and compare drug             
response models for a subset of the drugs used in the screen. 
In the second result’s subsection we describe the process of developing a drug             
response model for a TRXR1 inhibitor DKFZ-608 which was recently characterized           
in the lab of our collaborator Nikolas Gunkel. 
In the third result’s subsection we present a Shiny applications that visualizes            
samples’ drug response data for a selected pair of drugs, the idea of this interactive               
visualisation was proposed by Thorsten Zenz. 
7.2 Data and Methods 
7.2.1 Data 
In subsection 7.3.1 for modelling tests we use genomics and drug response data 
(AUC) from GDSC dataset.  
For training drug response model fro DKFZ-608 described in the section 7.3.2 we 
use genomics data from GDSC dataset.  
Shiny application described in the section 7.3.3 visualizes drug response (viability at 
individual concentrations) and genomic data from GDSC and CTRP datasets. 
7.2.2 Modelling (in the section 7.3.1) 
For feature selection we employed filter-type feature selection function gamScores          
from caret package (see details in the section 1.7.2). After feature selection we fit              
the model with N selected features (with lowest p-values) on the training set data.  
As a modelling method we used SVM with Radial base function (svmRadial) and             
elastic net regression. As accuracy measures we used R 2 (explained variance) and            
RMSE (root of mean squared error). 
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Feature selection, model fitting and accuracy evaluation were performed using the 
following procedure: 
1. We sort all samples by the values of drug response and then we take               
each third sample in the test set, therefore we get balanced (with respect to              
sensitive/resistant samples ratio) training (66%) and test (33%) sets. 
2. We perform feature selection on the training set. 
3. Then we fit the model with N selected features (with lowest p-values) on              
the training set data. Model’s hyperparameters are selected using         
cross-validation testing.  
4. We apply model to the test set, and calculate R 2 (calculated as a square               
of correlation between predicted and observed outcomes) and RMSE (root          
mean square error). 
7.3 Results 
7.3.1 Burkitt lymphoma drug sensitivity screen analysis 
This section presents the analysis of drug sensitivity screen of 42 blood cancer cell              
lines which was done in collaboration with Katarzyna Tomska and Thorsten Zenz.            
This work is described in the paper Tomska et al. 78 
18 out of 42 cell lines were Burkitt lymphoma (BL) lines which is highly aggressive               
B-cell lymphoma associated with MYC translocation. Cell lines were profiled with 32            
drugs, profiling included single-drug screen and drug-combination screen. I describe          
the analysis of this data below. 
We summarised drug sensitivity data from multiple concentrations of each drug           
using IC 50 and AUC metrics. (Fig. 20) In the subsequent analysis we used these              
two metrics as well as viability at individual concentrations. 
 
First thing we assessed was correlations between drug responses across all drugs            
(using viability data across all concentrations and AUC data) This analysis           
confirmed screening platform consistency (individual concentrations from the same         
drug clustered together) and identified groups of drugs with similar drug response:            
gefitinib and lapatinib -- EGFR pathway inhibitors, saracatinib and dasatinib --           
BCR-ABL/SRC inhibitors, idelalisib (PI3K), everolimus(mTOR) and MK-2206 (AKT)        
-- PI3K pathway, ibrutinib(BTK) and PRT062607 (SYK), idelalisib (PI3K) and          
PRT062607 (SYK), CHK inhibitor AZD7762 and DNA-PK inhibitor NU7441 (Fig.          
31). 
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Figure 31. Correlation between drug response vectors across all drugs, based           
on AUC response values. 
 
We were also interested in identifying subgroups of cell lines which show distinct             
drug sensitivity/resistance patterns. To this end we employed cell line-drug          
clustering (based on AUC and raw drug response values). We identified three            
clusters of response: Cluster I, Cluster II and intermediate group. (Fig. 32) Cluster I              
contained cell lines resistant to multiple drugs including inhibitors of PI3K and BCR             
pathways (ibrutinib, AVL-292, idelalisib, MK-2206, PRT062607 and everolimus).        
The cluster consisted of resistant BL and myeloma (MM) cell lines. Cluster II             
showed the strongest response to BCR and PI3K inhibitors and to a number of              
other inhibitors including SRC inhibitors (dasatinib, saracatinib). The intermediate         
group showed heterogeneous response driven by cell line-specific genotype         
context.  
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Figure 32. Heatmap with individual concentration raw viabilities across all drugs and            
all cell lines. Values plotted are raw viabilities-mean viability(across all cell lines for             
certain drug), range is [-100,100]. Cluster labels are shown next to cell line names. 
 
In order to analyze results from combinatorial screen for each tested drug pair we              
calculated Combination Index (CI) which is measure of drug synergy/antagonism: 
, 
where IC 50,A and IC 50,B are IC50 values for individual library drugs; C A,50 and C B,50              
are concentrations of drug A and B at which they were used in combination which               
lead to 50% viability. 84 
We defined combinations with CI < 0.85 as synergistic, those with 0.85 < CI < 1.15                
as additive and combinations with CI > 1.15 as antagonistic. To get an overview of               
combination effects in BL we clustered CI values across all drug pairs and cell lines               
(Fig. 33). 
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Figure 33. Combination Index values (CI) heatmap across all tested drug pairs            
and all cell lines. Blue color denotes synergistic pairs, red color denotes            
antagonistic pairs. 
 
Combinatorial screen consisted of three types of drug combinations: combinations          
with ibrutinib (BTK inhibitor), with idelalisib (PI3K inhibitor) and with OTX015 (BET            
inhibitor).  
The majority of drug combinations with ibrutinib were additive, lowest CIs were            
observed for its combinations with MK2206 (AKT inhibitor) and doxorubicin (DNA           
intercalating agent). 
Idelalisib was synergistic in combinations with JQ1 (BET inhibitor),         
chemotherapeutics, MK2206 (AKT inhibitor), PRT062607 (SYK inhibitor). 
Multiple strong synergistic effects were observed for OTX015. The lowest CI           
scores were found for SNS-032 (CDK2/7/9 inhibitor), inhibitors of PI3K/AKT/mTOR          
and BCR pathway inhibitors. Combinations of OTX015 with thapsigargin and          
YM155 were antagonistic. Also the important finding was that synergy for OTX015            
with idelalisib, MK-2206, everolimus and SNS-032 were observed at concentrations          
in vitro that can be safely administered in the clinical setting in  vivo . 
 
We also tested drug response models for 20 drugs (see Figure 34 and Table 21)               
that were tested both in this screen and in GDSC study. For these tests we used                
molecular and drug sensitivity data from GDSC 34 . For training we used data either             
from all cell lines (pan-cancer training, ~1000 samples) or from lymphoma cell lines             
(lymphoma training, ~50 samples). In order to test prediction accuracy we applied            
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models to genomic data from test panel of 16 Burkitt lymphoma cell lines (those cell               
lines we tested in our screen and were profiled in GDSC study).  
 
 
Figure 34. Overview of the model analysis in section 7.3.1. Modelling tasks (drug             
responses) and tested parameters (modelling method, feature type, # of variables, tissue            
specificity) are shown. 
 
Table 21. List of drugs (with their molecular targets) used in the screen for which we                
built drug response models. 
Drug Molecular target Drug Molecular target 
Afatinib EGFR, ERBB2 Nutlin-3 MDM2 
AZD7762 CHK Obatoclax BCL-2 
CAL-101 (Idelalisib) PI3K Olaparib PARP 
Dasatinib BCR-ABL Ruxolitinib JAK 
Doxorubicin Topo II Saracatinib SRC/BCR-ABL 
Gefitinib EGFR Selumetinib MEK 
JQ1 BET Thapsigargin ATPase, Ca++  
transporting 
Lapatinib EGFR, ERBB2 Trametinib MEK 
MK-2206 AKT Vorinostat HDAC 
NU-7441 DNA-PK YM155 survivin 
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We made two series of tests -- one using all the molecular features (expression,              
mutation, gain/loss and methylation information ) and the other using only mutation            
and gain/loss features. In both series we tested SVM and Elastic net models with              
either 200 or 1000 variables with highest correlation with drug response. Average R 2             
for tests with all molecular features and tests with only mutation + gain/loss features              
are present in the Table 22. Results for all drugs from tests with all molecular               
features are shown in the Fig. 35. 
 
Table 22. Average R 2 for tests with all molecular features and tests with only mutation +                
gain/loss information 
 ML method # of variables Pan-cancer training Lymphoma training 
All molecular  
features 
SVM 200 0.092 0.114  
1000 0.099 0.118 
Elastic net 200 0.124 0.126 
1000 0.098 0.165 
Only 
mutation +  
gain/loss 
features 
SVM 200 0.084 0.084 
Elastic net 200 0.103 0.169 
 
 
 
Figure 35.  Average R 2 values for all drugs (models with all genomic features).             
Bar color reflects the training type: red -- pan-cancer training, blue -- lymphoma             
training. 
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We also assessed an influence of training set imbalance on model accuracy by             
correlating class imbalance for each drug with average R 2 for a drug. We calculated              
class imbalance using the formula: class imbalance= , where      0.5 || − # sensitive#sensitive + # resistant   
# of sensitive and # of resistant were calculated as number of samples with AUC               
below and above the median AUC value respectively. Results are shown in the             
Table 23. 
 
Table 23. Spearman correlation between class imbalance and R 2  
 Pan-cancer Lymphoma 
All genomic features (mostly 
expression features due to 
FS) 
-0.06 -0.26 
Mutation + gain/loss 
features 
-0.14 0.16 
 
Summary of the results: 
● Lymphoma models almost in all cases outperform pan-cancer models 
● Elastic net models outperform SVM models 
● Models trained on mutation + gain/loss features only perform just slightly           
worse than models trained on all features (exp+mut+gain/loss) 
● Depending on molecular data type used for training, sets of most explainable            
drugs are different: 
– using all(mostly expression) features: Thapsigargin, Lapatinib, JQ1,        
Nutlin-3, NU-7441, MK-2206, Afatinib, AZD7762 
– using mutation and gain/loss features: Nutlin-3, Doxorubicin, Selumetinib,         
Obatoclax, CAL-101, Thapsigargin 
● For most of the drugs lymphoma-trained models give more accurate          
predictions than pan-cancer models. However for some drugs it's the          
opposite especially for Nutlin-3 , AZD7762, Afatinib, Trametinib. 
● Class imbalance has a slightly negative influence on accuracy. 
7.3.2 Drug response prediction model for DKFZ-608 compound 
This section describes the work performed in collaboration with Nikolas Gunkel           
(Department of Drug Discovery, German Cancer Research Center) on         
characterization of DKFZ-608 chemical compound. DKFZ-608, a homoleptic        
dithiocarbamate gold complex, was discovered in Drug Discovery Department. It          
was characterized as TRXR1 ( thioredoxin reductase ) inhibitor with selective         
anti-SCLC (small cell lung cancer) activity 85 . 
 
Drug response to DKFZ-608 was measured in 75 cell lines (in the Department of              
Drug Discovery) and IC 50 values were obtained. 43 out of these 75 cell lines were               
also genomically profilled in GDSC dataset, this allowed us to perform drug            
response-genomics associations analysis on these 43 cell lines. We assessed          
correlation between each individual genomic feature vector (expression/ copy         
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number/ mutation) and the vector drug response (i.e. vector of IC 50 values). After             
correcting for multiple testing using “Benjamini-Hochberg” method we ended up with           
307 gene expression features with adjusted p-values below 0.05. 
 
We analysed this 307-gene list using DAVID annotation tool. 86  Identified functional           
clusters with highest enrichment scores included “Nucleus and transcription         
regulation”, “DNA damage/ DNA repair”, “cell cycle and mitosis”, “mRNA          
processing” and “zinc finger” (Table 24). 
 
Table 24. Summarised results of DAVID Functional Annotation clustering. 
Cluster Annotation Terms Enrichment score 
1 Nucleus, transcription, DNA-binding 9.56 
2 DNA damage/repair 3.05 
3 Cell cycle 2.42 
4 RNA binding 2.42 
5 PAS domain 2.31 
6 negative regulation of gene expression,     
epigenetic 
2.25 
7 Zinc fingers 2.22 
 
Using this 307 gene expression features we built an ensemble drug response            
prediction model consisted of one Support Vector Machine (with Radial base           
function) and one Random Forest model and predicted IC 50 values for remaining            
937 GDSC cell lines (i.e. for those cell lines which were not tested with DKFZ-608               
compound). Later 14 of these 937 cell lines were tested with DKFZ-608 and ranking              
of observed IC 50 values was consistent with ranking of corresponding predicted IC 50            
values, R 2 =0.36. When we looked at PCA plots for these newly tested 14 NSCLC              
(non-small cell lung cancer) cell lines based on either all genomic features or             
selected 307 gene expression features (see Fig. 36) we realised that PCA plot             
based on all genomic features achieves better separation between samples with           
high and low IC 50  values compared to the PCA plot based on 307 expression              
features which suggests that a refined model trained on combined set of cell lines              
(43 + 14) will provide more accurate predictions. 
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Figure 36.  PCA plots showing NSCLC cell lines clustering. Color of the cell line              
label shows the level of corresponding IC 50 value. Upper PCA plot based on all              
genomic features, lower PCA plot based on 307 expression features previously           
selected for the drug response model. 
 
In addition we also identified drugs that produce similar response profiles by            
assessing the correlation between DKFZ-608 IC 50 vector (for 43 cell lines) and IC 50             
vectors from other drugs from GDSC dataset. The highest correlation (r=0.66) was            
found for Navitoclax, inhibitor of Bcl-2 family proteins. Also using expression data            
before and after treatment with DKFZ-608 in a number of cell lines (H209, Jurkat,              
Raji) we calculated expression signatures of the drug, i.e. obtained lists of genes             
that become up- and down-regulated upon treatment. We queried LINCS database 87           
(clue.io) using these lists and obtained information about compounds that produce           
similar expression changes. Classes of identified the most similar compounds          
included proteasome inhibitors, heat shock proteins inhibitors and NFkB inhibitors.  
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7.3.3 Shiny application for complex drug response visualization  
In order to analyse the difference between cell lines’ drug responses for a given pair               
of drugs (drug A vs. drug B) I was working on the corresponding drug response               
data visualization using Shiny technology. In the resulting shiny application user can            
define a dataset (GDSC or CTRP), a pair of drugs of interest (with an option of                
filtering drugs by molecular target) and cell lines with tissue filtering. 
Additionally the app provides an option of assessing molecular differences          
between cell lines that might drive observed difference in drug response. One can             
manually define two clusters on the plot and obtain a list of molecular features with               
the most significant differences between the two clusters ranked by t-test p-value.  
The application is available at shinyapps.io repository:       
https://drugs.shinyapps.io/drug_pair_ind_conc/ 
 
 
Figure 37. Interface of the Shiny application. Left panel allows a user to select the               
required data, plot on the right side is updated interactively. 
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8 DISCUSSION 
8.1 Improving accuracy of drug response prediction in        
cell lines 
8.1.1 Machine learning methods 
With the aim of improving accuracy of drug response predictions we tested a             
number of various model training approaches. I review and discuss the results            
here. 
 
Utilising information from drugs that share the same target via multi-task           
learning or learning on aggregated data.  We applied multi-task learning (using           
glmnet models) and learning on aggregated data (using Random Forest models) in            
order to co-utilize information on genomic-drug response associations for groups of           
drugs that share the same molecular targets (Table 5). Comparing performance of            
both approaches with a standard single-task approach we haven’t observed an           
improvement in predictive accuracy for multi-task models or models built on           
aggregated data. One possible explanation for this lack of improvement is that            
drugs can have the same target, but at the same time may exhibit differences in               
their inhibition profile 88 (i.e. have a different spectrum of additional targets).           
Therefore, just combining data from a group of drugs for model training should not              
necessarily help to identify more accurate associations and may not result in            
accuracy improvement. Simply getting more samples tested with the same drug           
would be more productive in terms of accuracy improvement (see discussion on            
training set sizes in the next subsection “Training set properties”). 
 
Modelling with feature interactions . Feature engineering is an important machine          
learning concept. Essentially feature engineering is the process of constructing new           
features from original features (i.e. from original data) with the idea that new features              
will provide better model performance. Here we tried two types of engineered            
features based on interactions between gene expression features ‒ binary gene           
pairs (BGP) and gene multiplications. Due to combinatorial complexity we were           
able to test only a small subset of all possible interactions, i.e. we focused on               
interactions between only 200 gene expression features with the highest correlation           
with outcome (drug response). Even with a limited initial set of features, BGP             
features showed a modest advantage in accuracy over original features when we            
used the random forest method for modelling (with elastic net method neither BGP             
nor gene multiplication features showed an advantage in accuracy). Typically,          
feature engineering approach can bring an advantage when it is used for            
incorporating domain knowledge, for example one could preselect genes for          
constructing new features not only by taking features with the highest association            
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with drug response but also taking all genes associated with cancer, e.g. from the              
Cancer Gene Census. 89  
 
Class imbalance. We examined how class imbalance (between sensitive and          
resistant samples) in training data influences the resulting accuracy of drug           
response prediction, using lasso models built for the group of 19 drugs (Table 5),              
and elastic net and SVM models built for the group of 20 drugs (Table 20). In both                 
cases the correlation between a measure of class imbalance and R 2 were negative             
but relatively small (less than -0.1). This may explain why no accuracy            
improvement was achieved when we tried modelling with weights where higher           
weights were assigned to under-represented sensitive samples. Therefore we         
would conclude that the level of drug-sensitivity data imbalance observed in the            
studied large pharmacogenomics datasets doesn’t constitute a problem for         
predictive performance. 
 
Choice of machine learning algorithm.  We compared accuracy of predictions          
(generated for seven drugs from CCLE dataset) between our method based on            
SVM, method from CCLE paper 31 based on elastic net and the second            
top-performing method from the DREAM challenge 81 that utilises random forest          
(see Table 12). The comparison shows that there is no a single method that              
outperforms the others for all drugs. 
Also we observed that in cases when all preprocessing, feature selection and            
model evaluating steps are kept the same and only modelling method (i.e. machine             
learning algorithm) changes, the resulting accuracy of drug response prediction          
shows a relatively modest variation. If we look at the models for erlotinib response              
in cell lines, the average R 2 for random forest models (tested on gCSI data; section               
3.4) is comparable with average R 2 for Support Vector Machines models (tested on             
data from CCLE, CTRP and GDSC; section 3.3): R 2 RF =0.23, R 2 SVM =0.19.  
8.1.2 Training set properties 
In the section 3.3 we described the analysis performed on the data from three              
largest pharmacogenomics datasets where we assessed the influence of different          
properties of training set on resulting model’s accuracy, now let’s review the main             
findings. 
  
Number of features . According to our results the number of top features selected             
for modelling (via filter-based feature selection), within the tested range of 10-500            
features, doesn’t influence the resulting accuracy of predictions, which rather          
depends on the strength of correlation between top feature(s) and the outcome.            
Also we observed similar outcome when we compared models with 200 and 1000             
features that were tested on Burkitt lymphoma lines (Table 21, section 3.6.1). 
 
Type of molecular data. We found that expression information has the highest            
predictive power compared to other data types (i.e. mutation and copy number            
information). This was also confirmed when we compared models with only           
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expression information and models with only mutation + gain/loss information on           
Burkitt lymphoma lines (Table 21, section 3.6.1). The same finding was observed in             
the analysis of DREAM challenge methods. 47 Probably expression information can          
explain drug response better than mutation and copy number information because           
it’s functionally closer to phenotypic level. 
 
Drug response metric. The choice of a drug response characterization metric has            
a serious impact on the accuracy of predictions. Having compared three drug            
response metrics for cell lines we found that the area under the drug response              
curve (AUC) provides the highest predictive performance (R 2 IC50 =0.111,        
R 2 AUC =0.186, R 2 viability_1uM =0.162). AUC combines information about drug efficacy        
and potency into a single value, and it was reported to be the robust metric               
previously. 90  
 
Size of training set. We also showed that the size of the training set is an                
important determinant for the accuracy of a model. In our tests based on gCSI data               
the average R 2 for models trained on cell lines from all tissues (n=329) was 0.267,               
while for models that used only cell lines from a certain tissue for each drug               
(n=26-68), the average R 2 was 0.102. Also results from the section 3.6.2 where we              
describe the process of model development for DKFZ-608 compound suggest that           
additional samples used for training lead to better model performance.  
 
Accuracy across drug panel. We observe that the accuracy of drug response             
prediction varies across the drugs, e.g. in our tests based on CCLE, CTRP and              
GDSC datasets and the AUC metric average R 2 ranges from 0.06 for Sorafenib to              
0.27 for PLX4720. Accuracy is quite heterogeneous across the drugs in the results             
in sections 3.2 and 3.6.1 as well. 
8.1.3 Comparing drug response prediction with other prediction        
tasks 
In the section 3.4 we described the analysis where we compared the task of drug               
response prediction with “positive control” tasks, namely tissue type prediction and           
prediction of cell doubling time. Now let’s review the results. 
 
We found that tissue type classification can be achieved with relatively high            
accuracy. Percentage of correctly predicted samples is 0.79 for cell line set, and             
0.89 for xenograft set. Accuracy of prediction depends substantially on the size of             
training set for each tissue class. When we additionally included tissues which have             
from 10 to 20 samples to our cell line modelling set, the average accuracy dropped               
from 0.79 to 0.64.  
While accuracy of tissue type classification is high on average, it varies across             
tissues. In a series of tests where we use equal number of samples per tissue (16                
samples in training set and 7 samples in test set), we found that we have the lowest                 
accuracy for lung samples, higher accuracy for breast samples, and the highest            
accuracy for pancreas, colon, skin and blood samples (Fig. 28). Interestingly this            
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ranking holds for both cell line and xenografts predictions. A fraction of lung             
samples is often misclassified as breast samples (and to a lesser extent the other              
way around) which results in comparatively lower accuracies for lung samples.           
This can be explained by the partial overlap between features that separate lung             
and breast samples from other samples, particularly expression of some          
transcription regulators genes and membrane protein genes. 
 
The second cellular phenotype we tried to predict was the cell line doubling time or               
slope of untreated tumor growth curve in case of xenografts. Here we got lower              
accuracy compared to the tissue type prediction. Average accuracy is quite           
consistent between cell lines and xenografts: R 2 cell lines =0.17, R 2 xenografts =0.19. The          
lower accuracy of prediction shows that unlike for tissue type there is less             
information about speed of cell division in the static expression data, which can be              
due to the post-translational regulation of cell cycle proteins activity. 
 
Thus, depending on cellular phenotype we want to predict with genomic data, the             
accuracy of prediction varies substantially. While expression data contain enough          
information to predict tissue of cell line with high accuracy, the accuracy for             
prediction of more complex dynamic phenotypes like doubling time or response to            
treatment is substantially lower.  
8.1.4 Cross-set consistency 
As we discussed in the introduction (section 1.6) the problem of consistency            
between pharmacogenomics dataset is crucial for biomarker discovery and         
consequently for drug response modelling. Indeed in the setting when we build a             
model using one dataset and assess model’s accuracy on another one the level of              
consistency between the two sets determines the accuracy of prediction,          
correlation between vector of cross-set AUC correlation values and vector of R 2            
values for 19 drugs was ~0.9 (section 3.2.5). 
  
In an attempt to battle cross-set inconsistency we tested two methods, simple cell             
line filtering and correction for general level of drug sensitivity (GLDS), GLDS            
method was proposed in the study Geeleher et al. 79 The idea of the method is to                
separate a drug-specific part of drug response signal from a general part which             
reflects intrinsic properties of cell line like tissue of origin, division rate, whether cell              
is primed to apoptosis, drug accumulation/afflux properties. The separation of          
drug-specific signal is achieved by taking into account drug responses from drugs            
that have unrelated mechanism of action to the drug in question.  
Firstly we tried to improve consistency between drug response data (AUC) alone.            
Cell line filtering improved consistency for almost all tested drugs at the obvious             
cost of reducing sample size (because of the cell lines that were filtered out).              
GLDS, in the simple form of subtracting mean of AUC values of unrelated drugs              
from AUC of the drug in question, didn’t improve the consistency. 
Secondly we applied GLDS to improve biomarkers’ (i.e. genomic feature - AUC            
association) consistency. Here we used GLDS version based on regression model           
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where outcome is a drug response and in addition to our main covariate, a              
biomarker, we add 10 additional covariates which are 10 principal components           
calculated on matrix composed of drug response vectors from unrelated drugs. We            
compared biomarkers’ association cross-set consistency across      
GDSC-CTRP-NIBR PDXE sets and across GDSC-CTRP-gCSI sets for common         
drugs between these groups of studies. Consistency was improved but only for            
some subsets of the drugs and datasets (e.g. for two out of three datasets). The               
fact that we have less improved cases between GDSC and either CTRP or gCSI              
compared to CTRP - gCSI indicates that it’s difficult to overcome the inconsistency             
that originates from difference in experimental techniques -- in GDSC study viability            
assays based on DNA content were used, in CTRP and gSCI viability assays were              
based on metabolic content. 36  
 
To conclude, inconsistency between pharmacogenomics datasets remain to be an          
important issue, and it seems that there is no universal computational solution for it.              
Users of pharmacogenomics data should be aware that due to the difference in             
experimental assays and data analysis techniques associations between genomic         
data and drug response may exhibit certain level of inconsistency. 59 
8.2 Using models trained on cell line data for drug          
response prediction in xenografts and patients 
The ultimate goal of pharmacogenomics research is to learn how to accurately            
predict drug response for patients. In the sections 3.4 and 3.5 we described the              
analyses of applicability of models trained on cell line data for drug response             
predictions in xenografts and patients respectively. Let’s now discuss these results. 
8.2.1 Xenografts 
As in the case of cell lines we found that the way of drug response quantification                
matters for resulting model performance. We compared different xenograft drug          
response metrics (Fig. 27) and found that simple metrics like “tumor volume (day             
21)” and “slope” perform better (average R 2 =0.23 and 0.25) than those which            
additionally take into account data from untreated controls -- “Integral response” and            
“Differential slope”, average R 2 =0.095 and 0.145 respectively (in this comparison          
xenograft data was used for model training and testing). 
 
Armed with these four response metrics we assessed our ability to predict drug             
response in xenografts using models trained on cell line data. We tested our             
predictions in four cohorts -- NSCLC treated with erlotinib, PDAC treated with            
gemcitabine, BRCA and NSCLC treated with paclitaxel. Only for the NSCLC cohort            
treated with Erlotinib our predictions were moderately accurate, i.e. positively          
correlated (r=0.5) with tumor volume and slope of the tumor growth curve (Fig.             
29b). Performance of the models built and tested on xenograft and cell line data              
separately can’t explain why this type of prediction worked only for erlotinib-treated            
cohort. Indirectly it shows that pharmacogenomic associations were consistent         
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between cell line and xenografts dataset only in the case of erlotinib, which has only               
one target-molecule EGFR, but not in the cases of more pleiotropic gemcitabine            
and paclitaxel which block DNA synthesis and cell division respectively.  
It’s important to note a data preprocessing aspect of this analysis, since cell             
expression data was profiled with microarrays, and xenograft data -- using           
RNA-seq (and available as fpkm values) we had to harmonise expression values            
between the two platforms. For that we applied z-score normalization (i.e           
subtracting the mean and dividing by the standard deviation of the samples) for             
each gene in cell line and xenograft datasets. We also tested a quantile             
normalisation with a different number of bins but overall prediction results didn’t            
improve.  
So far NIBR PDXE dataset is the only publicly available large scale            
pharmacogenomic xenograft study. With more xenografts and patient material         
screens available in the future, it will be possible to understand in which cases drug               
response associations are transferable between cell lines and xenografts/patients         
and in which cases they are not. 
8.2.2 Patients 
In the section 3.5 we described the process of applying classification models built             
on cell line data for prediction of treatment outcome (sensitive to treatment vs.             
resistant to treatment) in three different patient cohorts. By testing a range of             
models we identified a model with highest prediction accuracy in each cohort. While             
results for bortezomib were quite poor (balanced accuracy of the best model=0.53),            
best models for erlotinib and docetaxel showed reasonably good accuracy          
(balanced accuracy ~0.8 in both cases)  
 
It’s important to note that classification results depend on the way we binarize             
patient’s therapy response into two classes. This binarization is based on arbitrary            
criteria which are different for each cohort (see Table 14). Also there are multiple              
choices with respect to cell line drug response variable that is used for training the               
model. Similarly to our tests based on cell lines, AUC values selected for cell line               
response provided better classification on patients than IC50 values. We tested two            
type of binarization for cell line response -- without and with a “grey zone”, i.e.               
whether we binarize the whole spectrum of IC 50 or AUC values, or we take for               
model training only samples with high and low IC 50 /AUC values; the models that             
provided highest prediction accuracy were trained with “grey zone” option.  
 
Comparing pan-cancer models with tissue-specific models haven’t lead to a          
conclusive results, best model for erlotinib was trained on tissue-specific samples           
(lung samples) while best model for docetaxel was trained on samples from all             
tissues. Tissue-specific samples on one hand provide more relevant associations,          
but on the other hand samples from different tissues show more genetic variance             
which allows to identify genomic-response associations that are not seen in a            
smaller less heterogeneous group of samples.  
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At least for Docetaxel combining training data from different datasets results in a             
serious accuracy improvement (Table 16), which confirms our observation that          
training size is a determinant of model’s accuracy. Since training cell line data and              
patient expression data were coming from different Affymetrix microarray platforms,          
we used ComBat method from sva package to reduce the batch effect. According             
to PCA plots before and after batch effect correction expression values changed            
just to a very little extent, therefore we hypothesise that applying different approach             
for data homogenization might result in improved classification accuracy. 
Overall we see that applying cell line data for treatment response prediction in             
patients include many nuances with respect to data preprocessing and model           
training but in the end at least for some drugs it’s possible to come up with models                 
that predict binary treatment outcome with reasonable accuracy. 
8.3 Conclusions 
With a growing amount of pharmacogenomics data from model organisms (as well            
as patient genomic data) there is an increasing need in understanding how to             
integrate and extract meaningful information from this data. Concretely         
pharmacogenomics data can be used for generating machine learning models of           
drug response which, assuming the certain level of accuracy, can help in stratifying             
patient cohorts for clinical trials and in selecting efficient treatment strategy for            
individual patient. Our work provide some guidance for training and testing           
strategies for such models.  
 
We found that generally model’s predictive power depends on the type of molecular             
data, selected drug response metric, and the size of training set. It depends less on               
number of features (more important is the strength of correlation between top            
feature(s) and the outcome) and on class imbalance in training set. While predictive             
power varies across drugs (i.e. across models for different drugs) models built for             
the same drug using different machine learning methods accuracy usually show           
similar level of accuracy. We also found that unlike drug response tissue type can              
be predicted in cell lines and xenografts with quite high accuracy. Testing our ability              
to correctly predict response in xenografts and patients using models trained on cell             
lines produced positive results only in a fraction of tested cases, one of the positive               
examples was response to Erlotinib which was predicted with reasonable accuracy           
in xenograft and in patient cohort (two independent cohorts). 
 
Possible reasons for low predictive power of drug response models were concisely            
summarised in the recent review from Kalamara et al. 19 : 
“(i) noise in the data, and the aforementioned (ii) relative low number of samples when               
compared to the features, (iii) incomplete omics characterization, in particular in terms of             
proteomic and metabolomics, and (iv) limited readouts. Noise in the data can be either              
biological or technical and while methods to correct for technical variation are developed             
allowing us to bring datasets of different platforms together, the discussion on what is the               
correct way to apply them is not settled, adding uncertainty to downstream results. The low               
amount of samples toughens the discrimination of the true signal from noise. Incomplete             
“omics” characterization leaves open the possibility that the answer to our questions lies in              
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the things that have not been measured. Finally, the number of readouts is very relevant as                
subsequently the data used for models is vastly static (prior to treatment), while the effect of                
the drug is a dynamic process, whereby the drug modulates molecular components of the              
cell, that responds to this as an integrated system, as the target of the drug is often                 
embedded in a complex molecular network that includes multiple pathways, crosstalks among            
them, and feedbacks.” 
 
Some of the outlined problems actually reflect the directions for data generation            
which is already happening and probably will continue in the future: 
 
More functional and genomics data. More cell line screening data will be            
generated, 91 including drug combination screens (as the screen we describe in the            
section 3.6.1). Also data from other models is becoming available i.e. ex vivo             
profiling of patient material 25,26 , patient-derived organoid and patient derived         
xenograft screens 9,23,92  (PDO and PDX). In addition the amount of patient           
sequencing data will grow, and its integration with clinical data (NGS-EHR           
integration) will provide invaluable resource for biomarker discovery and         
validation. 93   
Richer multi-omics characterization . Methylation, proteomics and metabolomics       
profiling are already being used in combination with drug screens and will become             
more abundant. 
Richer drug response characterization. High-throughput imagine assays will provide         
a compliment to viability assays giving more detailed information on cellular           
changes upon the drug exposure. 94 Also expression changes characterization will          
continue to play an important role in describing cellular response to treatment. 87  
 
To conclude, in this study we used data from largest publicly available cell lines and               
xenograft pharmacogenomics screens to elucidate accuracy determinants of drug         
response prediction models. The amount of various multi-omics and drug response           
data in model organisms and humans will continue to grow and so will the              
opportunities for data integration as well as corresponding challenges. Gaining the           
ability to extract value out of this information in order to build models of drug               
response capable of accurate treatment outcome prediction in humans will facilitate           
translation of research findings into clinical practice and bring closer the era of             
personalised cancer medicine. 
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APPENDIX: REPRODUCIBILITY 
Chapters 2, 3, 6, 7 
Scripts and the instructions for the reproduction of the analyses from Chapters 2, 3, 
6 and 7 are available via github repository:  https://github.com/RomaHD/thesis_code 
 
In all scripts, the user needs to change the variable path to the repository root folder. 
Prior to running scripts from the chapters data.R script from the root folder should 
be executed in order produce the necessary data files for the Chapters 2,3,7. 
Chapter 2 
 name thesis's section 
1. drug_resp_consistency.R "Drug response consistency" 
2. biomarkers_consistency.R "Biomarkers' consistency" 
Chapter 3 
 name thesis's section 
1. multi_task.R "Multi-task glmnet models" 
2. aggregated.R "Modelling on aggregated data" 
3. feature_interactions.R "Modelling with feature interactions" 
4. weights.R "Modelling with weights" 
5. imbalance_and_consistency.R "How class imbalance and cross-set 
inconsistency affect prediction 
accuracy" 
Chapter 6 
Data: patient expression data files “bortezomib.patient.RData”, 
“erlotinib_data.RData”, and “pp.RData” should be downloaded from 
http://compbio.cs.toronto.edu/cp2p/  and extracted in the folder /data 
Scripts should be executed in the following order: 
 name description 
1. data_prep.R preprocess all data necessary for the modelling 
2. main_analysis.R performs the main anlysis 
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Chapter 7 
 name thesis's section/description 
1. bl_unsupervised_analysis.R "Burkitt lymphoma drug sensitivity 
screen analysis" -- usupervised part 
2. bl_modelling.R "Burkitt lymphoma drug sensitivity 
screen analysis" -- modelling 
3. dkfz608_modelling.R "Drug response prediction model for 
DKFZ-608 compound" 
4. shiny_data.R "Shiny application for complex drug 
response visualization" -- data 
preparation 
5. app.R "Shiny application for complex drug 
response visualization" -- app.R file of 
the application 
 
SessionInfo 
Session environment information 
#sessionInfo() 
R version 3.5.0 (2018-04-23) Platform: x86_64-redhat-linux-gnu (64-bit) Running 
under: CentOS Linux 7 (Core) 
Matrix products: default BLAS/LAPACK: /usr/lib64/R/lib/libRblas.so 
locale: [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C LC_TIME=en_US.UTF-8 
LC_COLLATE=en_US.UTF-8 
[5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8 
LC_PAPER=en_US.UTF-8 LC_NAME=C 
[9] LC_ADDRESS=C LC_TELEPHONE=C LC_MEASUREMENT=en_US.UTF-8 
LC_IDENTIFICATION=C 
attached base packages: [1] parallel stats graphics grDevices utils datasets 
methods base 
other attached packages: [1] PharmacoGx_1.8.3 e1071_1.7-0 doMC_1.3.5 
iterators_1.0.9 foreach_1.4.4 caret_6.0-80 ggplot2_2.2.1 
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[8] lattice_0.20-35 
loaded via a namespace (and not attached): [1] fgsea_1.4.1 colorspace_1.3-2 
class_7.3-14 rprojroot_1.3-2 lsa_0.73.1 pls_2.6-0 
[7] DRR_0.0.3 SnowballC_0.5.1 prodlim_2018.04.18 lubridate_1.7.4 
codetools_0.2-15 splines_3.5.0 
[13] mnormt_1.5-5 robustbase_0.93-0 knitr_1.20 RcppRoll_0.3.0 magicaxis_2.0.3 
broom_0.4.4 
[19] ddalpha_1.3.3 cluster_2.0.7-1 kernlab_0.9-26 sfsmisc_1.1-2 mapproj_1.2.6 
compiler_3.5.0 
[25] backports_1.1.2 assertthat_0.2.0 Matrix_1.2-14 lazyeval_0.2.1 limma_3.34.9 
htmltools_0.3.6 
[31] tools_3.5.0 bindrcpp_0.2.2 igraph_1.2.1 gtable_0.2.0 glue_1.2.0 RANN_2.5.1 
[37] reshape2_1.4.3 dplyr_0.7.5 maps_3.3.0 fastmatch_1.1-0 Rcpp_0.12.17 
slam_0.1-43 
[43] Biobase_2.38.0 gdata_2.18.0 nlme_3.1-137 psych_1.8.4 timeDate_3043.102 
gower_0.1.2 
[49] stringr_1.3.1 gtools_3.5.0 DEoptimR_1.0-8 MASS_7.3-50 scales_0.5.0 
ipred_0.9-6 
[55] relations_0.6-8 RColorBrewer_1.1-2 sets_1.0-18 yaml_2.1.19 gridExtra_2.3 
downloader_0.4 
[61] rpart_4.1-13 stringi_1.2.3 NISTunits_1.0.1 plotrix_3.7-2 randomForest_4.6-14 
caTools_1.17.1 
[67] BiocGenerics_0.24.0 BiocParallel_1.12.0 lava_1.6.1 geometry_0.3-6 
rlang_0.2.1 pkgconfig_2.0.1 
[73] bitops_1.0-6 evaluate_0.10.1 pracma_2.1.4 purrr_0.2.5 bindr_0.1.1 
recipes_0.1.3 
[79] labeling_0.3 CVST_0.2-2 tidyselect_0.2.4 plyr_1.8.4 magrittr_1.5 R6_2.2.2 
[85] gplots_3.0.1 dimRed_0.1.0 sm_2.2-5.5 pillar_1.2.3 foreign_0.8-70 withr_2.1.2 
[91] survival_2.42-3 abind_1.4-5 nnet_7.3-12 tibble_1.4.2 KernSmooth_2.23-15 
rmarkdown_1.10 
[97] grid_3.5.0 data.table_1.11.4 marray_1.56.0 piano_1.18.1 ModelMetrics_1.1.0 
digest_0.6.15 
[103] tidyr_0.8.1 stats4_3.5.0 munsell_0.5.0 celestial_1.4.1 magic_1.5-8 tcltk_3.5.0 
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Chapters 4, 5 
Scripts and the instructions for the reproduction of the analyses from Chapters 4 
and 5 are available via github repository: 
https://github.com/RomaHD/DrugRespPrediction 
(subfolders “analysis1” and “analysis2” respectively) 
 
In all scripts, the user needs to change the variable path to the repository root folder. 
Analysis I (Chapter 4) 
Scripts should be executed in the following order: 
 name description 
1. data_for_analysis1.R obtains data from PharmacoGx and 
preprocess it for a subsequent analysis 
2. analysis.R performs the analysis and saves results into 
results_table.RData 
3. plotting_R2.R produces figures 2a (Fig. 22a in this thesis), 
2b (Fig. 22b) and supplementary figures s3, 
s4, s6 (Fig. 24), s7, s8 (Fig. 25), s9 
4. top_features.R calculates and saves molecular features 
associated with drug response vectors and 
produces figure 2c (Fig. 22c) 
5. modelling_obs_pred.R produces predictions for each modelling task 
and saves them into raw_predictions2.RData 
6. plotting_obs_vs_pred.R produces figure 3 (Fig. 23) and supplementary 
figures s5-1, s5-2, s5-3 
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Analysis II (Chapter 5) 
Data: gCSI molecular data, particularly files “gcsi.genomics.rda”,       
“gcsi.genomics.feature.info.rda”, and “gcsi.line.info.rda” should be downloaded from       
http://research-pub.gene.com/gCSI-cellline-data/compareDrugScreens_current.tar.
gz and extracted in the folder analysis2/data 
Scripts should be executed in the following order: 
 name description 
1. nibr_preprocessing.R preprocess molecular and drug response 
xenograft data 
2. main_analysis.R performs the analysis, saves results and 
produces supplementary figures s11-1 
and s11-2 
3. tissue_classification_equal
_groups.R 
performs tissue classification for the case 
with equal number of samples per each 
tissue and produces figure 4 (Fig. 28 in 
this thesis) 
4. plotting_obs_vs_pred.R produces figure 5a (Fig. 29a) 
5. drug_resp_gcsi_to_nibr.R creates and tests model for xenograft 
predictions trained on cell line data, 
produces figure 5b (Fig. 29b) and 
supplementary figure s10 
 
SessionInfo 
Analysis has been done in the following session environment. 
#sessionInfo() 
R version 3.4.4 (2018-03-15) Platform: x86_64-redhat-linux-gnu (64-bit) Running 
under: CentOS Linux 7 (Core) 
Matrix products: default BLAS/LAPACK: /usr/lib64/R/lib/libRblas.so 
locale: [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C LC_TIME=en_US.UTF-8 
[4] LC_COLLATE=en_US.UTF-8 LC_MONETARY=en_US.UTF-8 
LC_MESSAGES=en_US.UTF-8 
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[7] LC_PAPER=en_US.UTF-8 LC_NAME=C LC_ADDRESS=C 
[10] LC_TELEPHONE=C LC_MEASUREMENT=en_US.UTF-8 
LC_IDENTIFICATION=C 
attached base packages: [1] splines stats graphics grDevices utils datasets 
methods base 
other attached packages: [1] PharmacoGx_1.8.3 ggfortify_0.4.5 gam_1.15 
foreach_1.4.4 caret_6.0-78 
[6] ggplot2_2.2.1 lattice_0.20-35 survcomp_1.28.5 prodlim_1.6.1 survival_2.42-3 
loaded via a namespace (and not attached): [1] nlme_3.1-137 lsa_0.73.1 
survivalROC_1.0.3 bitops_1.0-6 
[5] lubridate_1.7.3 dimRed_0.1.0 RColorBrewer_1.1-2 SnowballC_0.5.1 
[9] tools_3.4.4 R6_2.2.2 rpart_4.1-13 KernSmooth_2.23-15 [13] sm_2.2-5.4 
lazyeval_0.2.1 BiocGenerics_0.24.0 colorspace_1.3-2 
[17] rmeta_3.0 nnet_7.3-12 withr_2.1.1 tidyselect_0.2.4 
[21] gridExtra_2.3 mnormt_1.5-5 compiler_3.4.4 Biobase_2.38.0 
[25] slam_0.1-42 caTools_1.17.1 scales_0.5.0 sfsmisc_1.1-2 
[29] DEoptimR_1.0-8 psych_1.7.8 robustbase_0.92-8 randomForest_4.6-12 [33] 
relations_0.6-7 stringr_1.3.0 digest_0.6.15 foreign_0.8-70 
[37] pkgconfig_2.0.1 plotrix_3.7 limma_3.34.9 maps_3.3.0 
[41] rlang_0.2.0 ddalpha_1.3.1.1 MLmetrics_1.1.1 SuppDists_1.1-9.4 
[45] bindr_0.1 BiocParallel_1.12.0 gtools_3.5.0 dplyr_0.7.4 
[49] ModelMetrics_1.1.0 magrittr_1.5 Matrix_1.2-14 Rcpp_0.12.15 
[53] celestial_1.4.1 munsell_0.4.3 piano_1.18.1 stringi_1.1.6 
[57] MASS_7.3-50 gplots_3.0.1 plyr_1.8.4 recipes_0.1.2 
[61] grid_3.4.4 gdata_2.18.0 parallel_3.4.4 mapproj_1.2.6 
[65] pillar_1.2.1 fgsea_1.4.1 igraph_1.2.1 xgboost_0.6.4.1 
[69] marray_1.56.0 reshape2_1.4.3 codetools_0.2-15 stats4_3.4.4 
[73] fastmatch_1.1-0 CVST_0.2-1 NISTunits_1.0.1 glue_1.2.0 
[77] downloader_0.4 data.table_1.10.4-3 bootstrap_2017.2 gtable_0.2.0 
[81] RANN_2.5.1 purrr_0.2.4 tidyr_0.8.0 kernlab_0.9-25 
[85] assertthat_0.2.0 DRR_0.0.3 gower_0.1.2 broom_0.4.3 
[89] pracma_2.1.4 e1071_1.6-8 class_7.3-14 timeDate_3043.102 
[93] RcppRoll_0.2.2 tibble_1.4.2 iterators_1.0.9 cluster_2.0.7-1 
[97] sets_1.0-18 bindrcpp_0.2 lava_1.6 ROCR_1.0-7 
[101] magicaxis_2.0.3 ipred_0.9-6 
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